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ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is an “umbrella” term for the broad spectrum of
the disease that begins from the simple steatosis to more progressive stages of
nonalcoholic

steatohepatitis

(NASH),

that

includes

hepatocellular

ballooning,

inflammation, and fibrosis. NAFLD is a growing epidemic globally, with 25% of the
population predicted to be diagnosed with this disease. Liver biopsy is the only definitive
method of diagnosis, despite the widespread use of sonography and elastography to
predict the disease state. There is no current FDA approved medication for NAFLD/NASH.
This is partly due to the lack of translatable disease model to predict the whole spectrum
of the disease in humans as well as lack of definitive biomarker to predict the disease
state. The goal of this dissertation is (1) To build an in vitro model for NAFLD to study the
influence of fat over-load on xenobiotic as well as lipid metabolizing proteins (2) To use
the model to help identify novel biomarkers in liver tissue to characterize the early stages
of disease.
Manuscript I: In recent times, there are numerous invitro models relevant to humans
developed to predict the disease state. They involve monoculture, coculture and as well
as multicellular culture in both 2D and 3D models to best represent the physiology and
working of liver in the disease state. In this review, we have explored all the existing in
vitro models of NAFLD relevant to humans as well as highlight the technological gaps in
the current in vitro models for future development.
Manuscript II: Human hepatic carcinoma cell lines are commonly used in in vitro studies
of lipid and xenobiotic metabolism, as well as glucose regulation in normal and disease
state. However, their validity is still under debate due to the variable expression of proteins
in the cell lines and human hepatocytes. In this present study, we used a data independent
acquisition based total protein approach (DIA-TPA) to quantify the protein abundance in

the different cell lines versus (vs.) cryopreserved human hepatocytes (cHH) and human
liver tissue (HLT). For this purpose, the global proteome from the whole cell homogenates
of HepaRG, HepG2, Huh7 cell lines were compared to cHH and HLT. The MS2 spectra
for all detectable peptides were quantified using Spectronaut™. In summary, 2715, 2578,
2874, 2717 and 3083 proteins in, HepaRG, HepG2, Huh7, cHH and HLT, were identified
at 1% FDR, respectively. The global proteome of the cHH significantly differed from the
cancer hepatic cell lines. Within the cell lines, the global as well as ADME protein profile
of HepaRG most closely correlated with cHH, with 84 out of 101 ADME proteins, identified
in HepaRG cells. Within gluconeogenesis and glycolysis pathway, Huh7 cell line
expressed proteins in high abundance in contrast to the other groups. Therefore, we show
that the comparison demonstrates the capability of untargeted global proteomics to detect
the differences in protein expression among the different groups. In addition, this study
provides a comprehensive database of information to aid study design and model
selection.
Manuscript III: To manage NAFLD and related co-morbidities, patients are administered
with an array of pharmacological agents. Therefore, understanding of the effect of NAFLD
on drug disposition is warranted. Using a HepaRG model, we aimed to mimic steatosis in
vitro, and to examine its effects on drug-metabolizing enzymes (DME) and transporters.
HepaRG cells, differentiated in-house, were exposed to a mixture of saturated and
unsaturated fatty acids (1:2 ratio of 0.5 mM palmitate and oleate complex conjugated to
BSA for 72h) and were subjected to RNA sequencing and proteomic analyses. Lipid
accumulation was ascertained by Oil Red O (ORO) staining and triglyceride (TG)
quantitation and cell viability by WST-1 determination. The treatment condition resulted in
~6-fold increase in TG concentration without reducing cell viability. RNA sequencing of
lipid-loaded and control cells identified a total of 393 differentially expressed transcripts

(89 up- and 304 down-regulated). Moreover, lipid loading resulted in significant downregulation of mRNA transcripts of transcription factors, NR1I2 (-1.18) and HNF4α (-0.55),
phase 1 DMEs including CYP1A2 (-3.25), 2B6 (-2.02), 2C8 (-1.48), 2C9 (-2.00),2C19 (1.32) and 3A4 (-1.87), phase 2 DMEs including UGT1A6 (-0.36) and 2B7 (-1.09),
SULT2A1 (-0.75) and 1E1 (-1.41) as well as clinically relevant transporters such as
ABCC11 (-1.36), ABCG5 (-1.66), SLC10A1(-1.63) and SLCO2B1(-1.49). However, the
protein expression did not show a significant change. Furthermore, lipid loaded cells
significantly upregulated AKR1B10 mRNA (2.17) and protein (0.99) that may regulate lipid
as well as xenobiotic metabolism.
Manuscript IV: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic, present in
over 10% of the world population, despite the majority of the population being
undiagnosed. Liver biopsies are the only gold standard available for the confirmation of
disease state. Other non-invasive diagnostics such as ultrasound and MRI are either
inaccurate or expensive for routine use. Many markers for disease state are available that
detect the onset of inflammation and fibrosis from moderate-to-high accuracy. However,
there is a huge gap in specific biomarkers that can distinguish the NAFLD liver tissue from
normal in early stages of the disease. Using SWATH-MS based Data-independent
acquisition (DIA) strategy the dysregulated proteins in the in vitro model of hepatic
steatosis was compared with human liver tissue (n=116) showing progressive stages of
NAFLD. More than 2,500 proteins were identified in HepaRG and human hepatocyte
model as well as human liver tissue. Within the hepatocyte model, 40 proteins were
dysregulated in steatosis. These proteins were screened in liver tissue and 6 common
proteins were identified. The sensitivity and selectivity of the markers were analyzed using
receiver-operative curve (ROC) for the following markers PLIN2 (0.77), ANXA1(0.70),

H2AFY (0.80), SNX1 (0.67), GCHFR (0.69), APO (0.69) and all the above markers
showed significance P <0.05.
Conclusion. This work demonstrates that in vitro human relevant disease model has the
potential to explain the effect of NAFLD. Subsequently, the in vitro models when used in
conjunction with human liver tissue aid in identification of novel biomarkers that may have
therapeutic and diagnostic value.
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PREFACE
The following body of work is presented in manuscript format which constitute four major
chapters. The publication statuses of each manuscript are as follows:
Chapter 1: Preclinical In Vitro Models of Non-Alcoholic Fatty Liver Disease: A MiniReview
Manuscript 1: In Preparation for submission to Journal of Pharmacology and Experimental
Therapeutics
Chapter

2:

Comparative

Proteomics

Analysis

of

Cryopreserved

Human

Hepatocytes and Hepatic Cell Lines Using SWATH-MS Reveal Significant Variations
in Proteins Involved in Energy, Lipid and Xenobiotic Metabolism
Manuscript 2: In Preparation for submission to Molecular & Cellular Proteomics
Chapter 3: Transcriptomic and Proteomics Analysis of a Lipid-Loaded HepaRG
Model for Steatosis Reveals Altered Regulation in Lipid and Xenobiotic Metabolism
Manuscript 3: In Preparation for submission to Liver International
Chapter 4: Data-Independent Acquisition-Based Quantitative Proteomic Analysis
Reveals Potential Biomarkers of Non-Alcoholic Fatty Liver Disease
Manuscript 4: In Preparation for submission to Clinical Proteomics
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JUSTIFICATION OF RESEARCH
1. NAFLD Background
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease in the United States
as well as other parts of the world (Bellentani, 2017). A high-fat diet and lack of exercise
can lead to the accumulation of free fatty acids and tri-acyl glycerides (TAG) in
hepatocytes leading to the development of steatosis (Veteläinen et al., 2007; Koo, 2013).
Excess free fatty acids (FA) derived from diet or inflammation-induced lipolysis in
adipocytes results in the accumulation of TAGs in the form of lipid droplets (LDs) within
the hepatocytes. The occurrence of such LDs greater than 5% of hepatocytes is the
diagnostic measure for the onset of NAFLD and liver biopsy is the only form of conclusive
testing (Gan, Chitturi and Farrell, 2011; Gorden et al., 2015). The liver steatosis is often
termed as the “first-hit” in the progression of NAFLD. The “second-hit” is manifested via
the reactive oxygen species (ROS) induced stress leading to the infiltration of
inflammatory factors, hepatocellular ballooning and deposition of collagen fibers in
hepatocytes as observed in NASH and fibrosis (Caldwell and Argo, 2010). About 29% of
the patients diagnosed with NASH develop cirrhosis (Cohen, Horton and Hobbs, 2011).
Current treatment involves lifestyle management, which in most cases is proven
ineffective. Hence, our long-term goal is to identify non-invasive and conclusive diagnostic
methods for the identification of NAFLD as well as to discover a panel of biomarkers that
could be potential therapeutic targets for the pharmacotherapy of NAFLD.

2. Importance of studying the disease state with in-vitro systems
To study steatosis, it is crucial to identify the appropriate disease model. Nutrition and
energy uptake are the critical determinants for the onset of NAFLD; however, significant
differences exist in the manifestation of disease between humans and mice. Diet-induced

1

mouse models fail to recapitulate the spectrum of NAFLD as seen in humans (GómezLechón, Jover and Donato, 2009; Merrell and Cherrington, 2011). With a high-fat diet
(HFD) simple steatosis is established; however, male C57BL/6 mice fail to progress to
NASH even in the presence of high fructose-rich diet (Takahashi, Soejima and Fukusato,
2012). To establish NASH, most animal models are fed with methionine-choline-deficient
(MCD) diet that results in NASH without inducing obesity. Recent reports, suggest the
development of liver steatosis and fibrosis with high fructose (HF) rich diet (Cydylo, Davis
and Kavanagh, 2017). In addition, there are several genetically modified mouse models
such as, ob/ob, db/db that contain mutations in the leptin gene; however, they too fail to
recapitulate the full spectrum of the disease (Larter and Yeh, 2008). This physiological
mismatch makes it challenging to solely rely upon animal models for investigation of
NAFLD.
The use of primary human hepatocytes (PHH) or cryopreserved hepatocytes is considered
the gold standard for in-vitro studies (Lecluyse and Alexandre, 2010). However, the
availability of early-stage biopsy samples, limited time in culture before the onset of
dedifferentiation renders the utility of PHH as an ineffective tool for model development.
HepaRG cells are a human hepatocellular carcinoma cell line composed of a mixture of
both hepatocyte-like and biliary-like cells. They retain hepatic functions, expression of
liver-specific genes and drug metabolism capacity at levels comparable to that of PHH
(Guillouzo et al., 2007). Furthermore, they preserve their phenotype for over 2 weeks upon
differentiation (Aninat et al., 2006).

This provides for a good window for model

development and treatment modification.

3. The use of ‘Omics’ based technology in the identification of biomarkers

2

Omics technology is a broad term to denote the global detection of genes (genomics),
mRNA (transcriptomics), protein (proteomics) and metabolites (metabolomics). The total
mRNA in a cell or an organism provide a template for the translation of the expressed
protein. The transcriptome can be analyzed using RNA sequencing method to provide an
unbiased read-out of the all the expressed transcripts, the copy number of the individual
transcripts as well as the presence alternatively spliced transcripts between disease and
healthy state. This method of untargeted approach aids in the identification of novel genes
that are over/under-expressed in disease state and embody a huge potential towards
biomarker identification.
Additionally, shotgun or bottom-up proteomic approach is emerging as a powerful tool for
analyzing proteolytic peptides of high intensity eluting at the same time in a chromatogram
chosen for fragmentation and quantification. The results generated are high throughput
and have a complete proteome coverage that out-weighs the traditional labor and
resource intensive western blotting techniques (Vildhede et al., 2015; Wiśniewski et al.,
2016). Data-dependent acquisition (DDA) methodology has been used more commonly in
untargeted analysis (Gu et al., 2018). However, bias associated with the abundant
peptides and the lack of sensitivity to quantify low-abundance proteins rendering limitation
towards the analysis of individual protein of interest that are present in low expression(Shi
et al., 2018). Hence, sequential window acquisition of all theoretical mass spectra
(SWATH) analysis (AB Sciex, Concord, Canada) that follows a Data Independent
Acquisition (DIA) methodology is used to compare the relative expression pattern among
the groups (Huang et al., 2015; Gillet et al., 2012; Gao et al., 2017). This approach is
sensitive to capture the low abundant proteins which makes it a unique and reliable tool
to capture the differentially regulated proteins in the disease state.

3

Despite the unbiased, hypothesis generating potential observed in transcriptomics and
proteomics methods, there exists a high probability for false positive results. However,
high confidence exists when these results from different approach and systems are
analyzed together, and similar patterns emerge despite the method of detection. To date,
we do not have a unique panel of the biomarkers or a non-invasive method for conclusive
diagnosis of NAFLD, and this approach may aid to bridge the gap.
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Cryopreserved
undifferentiated
HepaRG

Proliferate HepaRG cells in
25cm2 flask for 14 days

5
Measure the mRNA expression
levels of whole genome with
RNA-seq.

Grow HepaRG cells to
confluence in 24 well plate for
14 days

Wash cells with 1X PBS. Add insulin (0.5,
1, 2,10, 50, 100 uM) for 10 min to assess
insulin response and measure pAKT/total
AKT. Measure other surrogate markers
such as triglycerides, cholesterol using
calorimetric assay.

Measure the protein levels with
SWATH analysis. Enzyme activity
measuring metabolite formation
using MS/MS.

Figure-1 Overview of the invitro model for hepatic steatosis using HepaRG cell line

Differentiate HepaRG cells in
presence of 2% DMSO in 24 well
plate for 14 days

Replace with media enriched with fatty acids
(oleic:palmitic acid, 2:1) for 24, 48 and 72 hrs.
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Abstract
Nonalcoholic fatty liver disease (NAFLD) is an “umbrella” term for the broad
spectrum of the disease that begins from the simple steatosis to more progressive stages
of nonalcoholic steatohepatitis (NASH), that includes hepatocellular ballooning,
inflammation, and fibrosis. NAFLD is a growing epidemic globally, with 25% of the
population predicted to be diagnosed with this disease. Liver biopsy is the only definitive
method of diagnosis, despite the widespread use of sonography and elastography to
predict the disease state. There is no current FDA approved medication for NAFLD/NASH,
due to the lack of definitive biomarker to predict the disease state or translatable disease
and/or model to predict the whole spectrum of the disease in humans. In this review, we
have explored all the existing in vitro models of NAFLD relevant to humans as well as
highlight the technological gaps in the current in vitro models for future development.

Keywords
Preclinical; NAFLD; in vitro models; NASH; Hepatic steatosis.
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1. Introduction
Hepatic steatosis is characterized by the accumulation of lipids (> 5% of the
hepatocytes) in the cytoplasmic region as micro and macrovesicular vacuoles. This may
progress to nonalcoholic steatohepatitis (NASH), which results in hepatocellular injury (1).
Steatosis is often reversible and self-limiting. However, ∼25% of the cases progress to
NASH, wherein the liver may become fibrotic resulting in permanent damage. In terms of
the worldwide incidence, it is noted that extreme variations occur in the reported range
between the studies (2). The current estimates around the incidence of nonalcoholic fatty
liver (NAFLD), ranges between 20-30% in Western countries and 5-18% in Asia,
suggesting it to become the leading cause of end-stage liver disease and transplantation,
in the next decade (3). The fluctuations in the estimates, is in part, associated with the
lack of definitive biomarkers to characterize the disease state as well as the limitations in
current testing methods. Due to these challenges, there are currently no US Food and
Drug Administration (FDA)-approved medication to treat NAFLD or NASH (4, 5).
Numerous risk factors have accentuated the development of NAFLD, namely, diet,
lifestyle, age, gender, ethnicity, genetics, and metabolic disorders that impact the lipid
metabolism and insulin resistance (Fig. 1.1) (2). Other risk factors involve, drug-induced
toxicity, as seen in tetracycline and amiodarone, and environmental pollutants, such as
bisphenol a (BPA), that may induce and ameliorate NAFLD (6, 7). Besides, the metabolic
deregulation observed in the disease state may also impact the disposition and dosing of
other concomitant medication within the patient population.
To investigate the drug deposition of the administered drugs due to changes in
hepatic metabolism in disease state as well as inspect the chemical-induced toxicity that
ameliorates NAFLD; early-stage screening tools that most represent the disease state in
humans, are warranted. These models are also advantageous during drug development

13

for examining various molecular entities against therapeutic targets that contribute to
disease progression, e.g., FXR agonists (8). Due to the widely acknowledged ethical and
financial requirements that limit the animal use in exploratory studies (9), system-oriented
approaches involving integrated into in vitro and in silico models to best predict the
changes in human liver physiology, are emerging as valuable tools to study the molecular
changes involved in the disease state (10).
In the forthcoming sections, we will provide context for the pathology of NAFLD,
risk factors associated with the disease progression as well as the current sophisticated
in-vitro human models that reflect the different stages underlying the etiology of NAFLD.
The aim of this review is to provide comprehensive information on the existing in vitro
models of NAFLD to aid the choice of appropriate model as well as highlight the
technological gaps in the current in vitro models for future development.
2. Pathology and Risk factors
Lipid accumulation in the hepatocytes is the starting point for hepatic steatosis.
However, with the severity of progression, the affected parenchyma is subdivided into
three categories: 5%-33%, 34%-66%, and > 66% as mild, moderate, and severe,
respectively (11). The occurrence of steatosis is spatially heterogenous in the liver, with
lipids localized to zone 3 in the early stages of disease in contrast to panacinar localization,
as seen with the progression of steatosis (12). This heterogeneity may lead to occasional
overestimation of the degree of steatosis by histopathologists. In addition, conventional
imaging (ultrasound, magnetic resonance imaging, or computed tomography), lack the
sensitivity to detect hepatic steatosis less than 30% (13). However, newer technologies
involving magnetic resonance imaging-estimated proton density fat fraction, and 1Hmagnetic resonance spectroscopy detect steatosis with high accuracy (14, 15).
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Steatosis often triggers the infiltration of inflammatory modulators via Kupffer cells
that result in hepatocyte ballooning, inflammation, and injury. At this point, the disease
progresses to nonalcoholic steatohepatitis (NASH), which may lead to fibrosis wherein the
healthy cells are replaced with scarred tissue due to the deposition of collagen. Recent
findings highlight the promising role of cytokeratin CK 8/18 to be used as a biomarker to
detect hepatocyte ballooning as their expression is significantly decreased in comparison
to normal hepatocytes (12), as observed in histological staining. Also, CK-18 fragments
detected in the plasma positively correlate with the severity of NASH (p < 0.001) (16).
NAFLD is observed at a higher incidence in cohorts with metabolic syndrome and
cardiovascular risk (Fig. 1.1)(17). Additionally, type 2 diabetes mellitus (T2DM) patients
display a high risk for developing NASH and a 2-to-4-fold risk of developing NAFL.
Ethnicity also plays a critical role with a higher rate of incidence seen in Hispanics and
Asians, followed by Caucasians (18). Possession of homozygous PNPLA3 allele
(rs738409) in the Hispanic population contributes to 2-fold higher hepatic lipid
accumulation (19). On the other hand, a lower incidence of steatosis is observed in
African-Americans in comparison to Caucasians. In addition, genetic polymorphism in the
TM6SF2 gene, involved in VLDL secretion, leads to a higher incidence of NAFLD. The
variant frequencies in TM6SF2 gene is found to be higher in whites, African-American,
and Hispanic races (19).
The occurrence of NAFLD increases with age an incidence of 20% in age group
under 20 to 40% or more in the age group above 60 (20). Diet enriched with
macronutrients and carbohydrates posit high risk in developing NAFL as well as its
progression. It can be worsened when coupled with a sedentary lifestyle and smoking (21,
22). Moreover, endocrine dysfunction, such as polycystic ovarian disorder (PCOS), is
often characterized by obese and insulin-resistant women (23). There are evidences that
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show PCOS with insulin resistance worsens hyperandrogenemia, which leads to NAFL. A
striking association of NAFL is also observed in patients with obstructive sleep apnea
(OSA), which is caused by a complete or partial obstruction of the airway. The incomplete
exchange of gases (hypoxemia and hypercapnia) leads to oxidative stress, recruitment of
pro-inflammatory factors, insulin resistance, and endothelial dysfunction. This may lead to
the evolution of NAFL to NASH (24).
3. In vitro models of Nonalcoholic fatty liver disease (NAFLD)
The current in vitro models for NAFLD is summarized in Table 1.1 and the overview of all
the models are illustrated in Figure 1.2

3.1 Monoculture systems
3.1.1

Hepatocellular Carcinoma (HepG2, Huh7, and HepaRG)
Human hepatocarcinoma cell lines have been widely used in the literature to model

NAFLD in vitro. The ease of propagation, reproducibility, and low cost for procurement
makes them an ideal candidate for preliminary model development. The majority of the
models for steatosis have been developed by exposing the cells to free fatty acids, namely
oleate (OA) and palmitate (PA) (Table 1.1). The choice of these fatty acids stems from the
high content of oleate and palmitate in triglycerides. Besides, clinical data show varying
levels of these free fatty acids (FFA) in blood ranging between ∼0.25-3.0 mmol/L,
moreover, they are chronically higher in individuals with obesity and/or diabetes.
Acute treatment (24h) with FFA mixture, induced all three cancer cell lines to show
dose-dependent lipid and triglyceride accumulation; on the other hand, with palmitate
alone, induced apoptosis, oxidative stress, and insulin resistance. Furthermore, the
addition of stearic acid showed induction of CYP2E1 activity in addition to the development
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of steatosis (26). Apart from fatty acid stimuli, other models assess the impact of glucose,
fructose, and insulin on the cell lines to mimic the onset of NAFL, as seen in increased
intake of dietary macronutrients (27). Lastly, steatosis was assessed in the HepaRG cell
line stimulated with oleate and palmitate, along with varying concentrations of IL6 (28).
The presence of IL6 not only induced NAFLD and NASH like phenotype, but also resulted
in significant downregulation of CYP2A6, 2B6, 2C19, 2C9, 3A4, and 3A5 mRNA after a
24h treatment (28).
In context to toxicological assessments, Tolosa et al. (2016) demonstrate the ability
of HepaRG cell line to appropriately flag the inducers of steatosis upon exposure to 16known steatogenic compounds (29).

Furthermore, treatment with tetracycline and

amiodarone after acute and repeated treatments induced steatosis, highlighting the
robustness of HepaRG, in predicting the drug-induced hepatotoxicity as well as its utility
for understanding the molecular mechanisms involved in the onset and progression of
disease state (7). In summary, these reports represent the possible impact of various
stimuli on the onset of hepatic steatosis and/or NASH. However, the results from cancer
cell lines are viewed with skepticism as the translatability of the observed impact on human
hepatocytes is unknown. In addition, it is well-known that Huh7 and HepG2 cell line
expresses the drug-metabolizing enzymes in low levels in comparison to human
hepatocytes (30, 31). Hence understanding the DME modulation could be a challenge.
However, HepaRG cells can be used to overcome this drawback as evidence show the
presence of comparable levels of DME to human hepatocytes.
3.1.2 Primary Human Hepatocytes (PHH)
Primary human hepatocytes are the current gold standard to study metabolism and
toxicity related effects of drugs. Donato et al. (2006), showed a model using hepatocytes
isolated from 17 steatotic and non-steatotic human liver. Upon harvest and seeding, the
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cells were treated with oleate and palmitate to maintain the hepatocytes in the state of
steatosis for 14 h and 36 h (32). As a result, lipid accumulation and triglyceride increase
were observed in the hepatocytes with steatosis. In addition, CYP1A2, CYP2A6, CYP2C9,
CYP2D6, CYP2E1, CYP2B6, and CYP3A4 mRNA, along with CYP1A2, CYP2A6,
CYP2C9, CYP2D6, CYP2E1, and CYP3A4 enzyme activity showed a significant reduction
in steatosis (32). This was the first study in which several human P450 enzymes have
been comparatively examined in a model of induced steatosis. This closely represented
the disease state; however, the hepatocytes in culture, start to lose their metabolic
capacity after 72h, and hence, a static, two dimensional (2D)-model cannot be
representative of long-term impact.
To mitigate the drawbacks of the 2D static model and to study the long-term impact
of triglyceride accumulation, three dimensional (3D) spheroids or 3D models using
scaffolds were developed (33). The 3D models using scaffolds were cultured in the
microfluidic device and LiverChip platform with continuous perfusion of media to mimic the
dynamic sinusoidal flow in the liver (34). This stabilized the hepatic metabolizing capacity
to over 14 days in culture. Subsequently, the model was treated with control and FFA
mixture (oleate and palmitate, 2:1) for 7d. As a result, increased levels of secreted
adipokines were noted; IGFβ1, PDK4, and FABP-1 genes associated with lipid
metabolism were upregulated; and a decrease in the metabolic rate of CYP3A4 and
CYP2C9 were also reported.
3.1.3 Induced Pluripotent Stem Cells derived Hepatocytes (iPSC-Hep)
Despite the fact that human hepatocytes are considered as gold-standard, they
represent several limitations, such as donor to donor variability, lack of availability, cost of
procurement, variability in proliferation, which introduce mutations and polymorphisms in
metabolic markers. Human-induced pluripotent stem cell (hiPSC)-derived hepatocytes
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(hiPSC-Hep) generated from mature hepatocytes overcome the limitations observed with
PHH. Henceforth, a model using hiPSC-Hep was co-treated with FFAs (oleate and
palmitate) and the ER stressor, thapsigargin (TG), to recapitulate NASH (8). This model
showed intracellular lipid accumulation via activation of denovo lipogenesis as well as its
association with ER related UPR network. In addition to the genes involved in lipid
metabolisms such as SREBP-1c, ACC1, and SCD1, and known markers of NASH such
as STC2 and FGF21 were upregulated. Henceforth, this model showed the potential to
induce NAFL and NASH successfully. Additionally, hiPSC-Hep demonstrates an added
advantage of having the potential to derive genotype-specific hepatocytes from patient
samples to understand the relevance of polymorphic genes (PNPLA3) in the signaling
network.
3.2

Co-culture systems

3.2.1 Micropatterned Primary Co-Cultures (MPCCs)
To maintain the longevity of primary human hepatocyte in culture, MPCCs were
developed to study the effects of hyper and hypoglycemia in hepatocytes. MPCCs
recapitulate the homotypic interactions with the primary human hepatocytes as well as the
heterotypic interactions of hepatocytes with supportive non-parenchymal cells (NPCs)
such as fibroblasts (35). MPCC model was facilitated by patterning 24-well plated with rattail collagen 1 at 500 µm diameter spaced 1200 µm away from each other. This enabled
the selective attachment of hepatocytes to collagen islands along with the 3T3-J2
fibroblasts covering the spaces between the islands. This study, for the first time, showed
the culture of PHH with fibroblasts, stabilized the PHH in culture for ~3 weeks, and was
used to understand the response to chronic treatment with varying concentrations of
glucose (35). Upon treatment with high glucose, insulin-responsive genes SREBF1 and
FASN were upregulated along with increased lipid accumulation in the hepatocytes,
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suggesting the shuttling of glucose to insulin-stimulated lipogenesis in the cells. Also,
hyperglycemia downregulated CYP2E1 transcripts. This model showed ‘selective’ insulin
resistance akin to type 2 diabetes mellitus (T2DM).
3.2.2 MPCCs with activated stellate cells
MPCCs were constructed with activated or growth arrested human stellate cells
(HSCs) as the supportive cell type (1 HSC: 12 PHHs using 2.5k HSCs) along with human
hepatocytes (36). The addition of proliferative stellate cells resulted in an increase in
albumin production and CYP3A4 activity in hepatocytes. However, severe distortion of
hepatocyte islands occurred in 2 weeks. Showing that the activated HSCs, proliferative or
growth-arrested, cannot support PHH functions to the same extent of 3T3-J2 fibroblasts.
3.3

Tri-culture systems

3.3.1 Micropatterned Tri-Cultures (MPTCs)
To stabilize the hepatocytes in long-term culture as well as induce NASH-like
phenotype with activated stellate cells, a micropatterned tri-culture model was introduced.
In this model, growth-arrested 3T3-J2s (90k cells per 24-well format) were mixed with
activated HSCs (2.5k), and this mixture was then seeded onto to micropatterned PHH
colonies (30k cells) (36). The ratio of stellate cells to PHH was corresponding to the
proportion in the human liver. In such micropatterned tri-cultures (MPTCs), albumin
secretion was higher than the levels seen in MPCCs. Besides, the supporting nonparenchymal cells (NPCs) stabilized the hepatocytes in culture. Upon the stimulus from
activated stellate cells for 13 d, significant levels of lipid-filled vesicles (containing acylglycerols and cholesterol esters) were observed. Besides, the upregulation of IL6 and
CRP protein, as seen in NASH, was observed. Downregulation of significant liver-specific
genes was observed, such as PXR, CAR, CYP3A4, CYP2A6, NTCP, MRP2, BSEP, and
FXR. Interestingly, MPTCs show collagen-I deposition by α-SMA-positive HSCs along
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with the upregulation in the mRNA of LOX and COL1A1 (36). In summary, MPTCs show
NASH/fibrosis like phenotype. Despite the well-maintained architecture, the model
occasionally induced distorted hepatocyte islands due to donor-to-donor variability.
Henceforth, human hepatocytes, and stellate cell lots in the development of this model
must be chosen after careful screening.
3.3.2 Trans-well culture
An in vitro model with the combination of coculture of stellate cells and fibroblasts in
trans-well and monoculture on hepatocytes in the culture plates was developed to model
NASH. The separation of stellate cells and fibroblasts from hepatocytes helped in
understanding the specific impact on hepatocytes. In addition to the culture, the model
was engineered to incorporate hemodynamic stress, hepatic sinusoidal flow, transport,
and finally exposed to lipotoxic risk factors such as glucose, insulin, free fatty acids (oleate
and palmitate) (37). Upon the stimulus, hepatocyte glucose output increased with
decreased insulin sensitivity. Increased levels of IL6, IL8, and ALT were observed along
with the activation of fibrogenic markers such as TGF-ß. This model showed
transcriptomics, proteomics, and lipidomics signature similar to that of NASH liver
biopsies.
3.4

Multi cell-culture systems

3.4.1 3D-Human Liver Micro-Tissues (3D-hLMT)
3D-hLMT model is the known closest in vitro culture system that mimic the in vivo
liver physiology. The model can recapitulate the multicellularity in 3D format and maintain
individual cell phenotype for over 5 weeks (38). PHH were co-cultured with NPCs such as
hepatic stellate cells, Kupffer cells, and endothelial cells. In this model, 0.5 mM of palmitic
acid (PA) induces a robust inflammatory as well as fibro-genic response in the 3D-hLMT.
PA significantly induced the expression of collagen related genes, α-SMA, TIMP1, IL8
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transcripts, as well as TGFβ gene activation pathway (38). Nevertheless, owing to its
complexity, these models are time-consuming and expensive to establish; in addition,
scalability is a limiting factor to use these models in routine high-throughput screening.
3.4.2 Induced Pluripotent Stem Cell (iPSCs) derived organoids
iPSCs derived from 11 human donors (healthy and diseased) were developed to
derive organoid comprising of hepatocyte, stellate, and Kupffer and biliary-like cells whose
genetic signature was confirmed from transcriptomics analysis. Upon stimulus with fatty
acids (800 µm of oleate) for 5 days, the human liver organoids (HLO) showed the stepwise
progression of NAFLD from steatosis, ballooning, inflammation, and fibrosis phenotypes
recapitulating NASH in the latter stages (39). In addition, atomic force microscopy
confirmed the severity of fibrosis conferred in the HLOs. This novel approach sets a unique
benchmark to understand the genotype-specific contributions on the progression of
disease state as well as contribute to therapies based on personalized treatment.
However, the significant limitations associated with this model must also be taken to
account. The donor to donor variability might affect the HLOs phenotype, such as NASH
and fibrosis (39). Additionally, the time and cost involved in the organoid development may
pose further limitations in routine usage.
3.5

The organotypic ex-vivo culture system

3.5.1

Precision-Cut Liver Slices (PCLS)

Many advancements have been noticed in the use of 2D and 3D monoculture to mimic
NAFLD. However, the complex interactions of multiple cell types such as hepatocytes,
Kupffer cells, stellate, and endothelial cells that induce inflammation, necrosis, and
consequently, fibrosis in NAFLD, is impossible to be recapitulated in a 2D and 3Dmonoculture. Human precision-cut liver slices (hPCL) retain the liver architecture with the
multi-cell interactions among the specialized liver-specific cell types as well as infiltrating
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lymphocytes to up to 5 days in culture (40). Henceforth, they make an excellent model to
study the changes observed during the different stages of NAFLD and test new therapies.
hPCLS model for NAFLD is developed as follows: (1) Resected liver tissue flushed
with ice-cold University of Wisconsin (UW) solution and ~ 1 cm thick tissue is prepared for
further processing. (2) Following this, a hollow cylindrical tissue drill is used to prepare
chunks of 5 mm diameter cores. (3) The cores are inserted in the tissue holder and cut
with the microtome (Krumdieck Tissue Slicer). (4) Liver sections of 5 mg weight and ~ 250
µm thick are prepared for further treatments. (5) hPCLS are treated with free fatty acids
(a mixture of oleic and linoleic acids, 0.1 mM) to mimic the hepatic steatosis, lipid
deposition, and lipotoxicity. Alternatively, opportunities to prepare hPCLS from cirrhotic
patients to assess therapeutic interventions also exist for future development. PCLS
makes ideal models, especially by maintaining the intact morphology of hepatocytes.
However, the limited time in culture and the inability to adapt to genetic changes such as
transfection or RNA silencing, makes it challenging to understand the impact of a specific
gene in the signaling pathways leading to disease progression.
4.

Conclusion
A translatable human in vitro model of NAFLD is the need of the hour. However, a

model that fits all-purpose, to study a "multiple-hit" disease state, such as NAFLD, poses
a highly relevant challenge to the research community. The majority of models developed
thus far represent 2D-static mode involving either PHH or human carcinoma cell lines.
However, it is impossible to study the whole spectrum of disease state using such simple
systems. Hepatic steatosis was well recapitulated using various stressors, such as free
fatty acids, glucose, and fructose, insulin, interleukins as well as other chemicals. A few
studies have advanced further, by including microfluidic the model to mimic the sinusoidal
flow as well as micropatterning to recapitulate the spatial organization of hepatocytes with
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the supporting NPCs. Sophisticated models with 3D-hLMT as well as iPSC-derived
organoids, only show a sneak-peak of the innovations coming up soon. This may allow for
the whole body to be modeled on the chip to understand the disease state beyond the
liver, by including the gut axis as well as adipose tissue. Such innovative tools will
contribute to new therapies as well as understanding other complexities that come with
the disease.
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5. Figures and Tables

Figure 1. 1: Risk factors associated with nonalcoholic fatty liver disease.
Abbreviations. NAFLD: Nonalcoholic fatty liver disease; NASH: Nonalcoholic
steatohepatitis; T2DM: Type 2 diabetes mellitus; PCOS: Polycystic ovarian syndrome; IR:
Insulin resistance; OSA: Obstructive sleep apnea; TG: Triglycerides.
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STEATOSIS (FATTY LIVER)

HEALTHY LIVER

NASH w/o FIBROSIS

NASH + FIBROSIS

Complexity
2D Monoculture

2D Coculture

3D Monoculture

3D Coculture

2D Triculture

Stimuli:
q Lipotoxicity
v Oleate,
Palmitate,
Stearic acid
q Glucose/Fructose
q Chemical induced
q IL6 and Insulin

3D Multicellular
organoids

3D Triculture
• Human
Hepatocytes,
Kupffer cells,
Activated Stellate
cells, Endothelial
cells

• HepG2, Huh7,
HepaRG cell lines
• Human
Hepatocytes

Figure 1. 2: In vitro models of nonalcoholic fatty liver disease.
Abbreviations. NASH: Nonalcoholic steatohepatitis; IL6: Interleukins 6.
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Table 1.1: Preclinical in vitro model for NAFLD.
Platform

Treatment

Conc.

Duration

Phenotype

Monoculture
HepG2

Oleate

0-1 mM

6h

↑ Lipid accumulation;
SREBP-1

Palmitate

0-1 mM

6h

↑Cytotoxicity;
↑
resistance; ↑DAG

8 mM

24 h

↑ Lipid accumulation; ↑ TG Progression to (42)
accumulation; ↑IL8 secretion NASH

Palmitate
conjugated
BSA (5:1)

to
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Oleate: Palmitate 0-2 mM
24 h
(1:1; 2:1, 0:3)
conjugated
to
BSA
Valproate
1, 2.5 and 5 24 h
µM

HepG2 cells culture in Oleate
microfluidic perfused Palmitate
device
Huh7

and

Relevance to [Ref.]
human
disease
↑ Hepatic
Steatosis

Insulin Progression to (41)
NASH

↑ Lipid accumulation; ↑TG Hepatic
accumulation
Steatosis

(43)

Concentration-dependent
Hepatic
increase in intracellular fat; ↑ Steatosis
CD36 and ↑DGAT protein
expression.

(44)

24h and 48 ↓ Lipid accumulation and TG NAFLD
h
than 2D static model.

Glucose only or 0.65-0.72
24 h
Glucose
and mM or 0.58 Fructose (G: F) 0.67 mM
(1:1)

(41)

G: F treatment ↑ TG Hepatic
accumulation; ↑ Cholestrol
Steatosis

(45)

(27)

Palmitate

HepaRG

0.2 - 0.8 mM
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8h

↑ ER stress

Oleate: Palmitate 0.2 mM
(2:1)

24 h

(47)

Oleate: Palmitate 0 - 1.2 mM
(1:1)

24 h

↑ Lipid accumulation;
NASH
↑IL8; ↑IL6 and TNF alpha
secretion
↑ Lipid accumulation
Hepatic
Steatosis
Steatotic compounds: ↑ lipid
accumulation and ↑ ROS
production.
↑
gene
expression
of
EHHADH
CROT MTTP ANGPTL3
IGFBP1 FOXA1 SREBP1C
PPARA PGC1A.
↑ Lipid accumulation; ↑TG
accumulation; ↑ADFP and
↑PLIN4 genes

Hepatic
Steatosis

(29)

Hepatic
Steatosis

(7)

↑ Lipid accumulation; ↑TG Hepatic
accumulation
Steatosis

(6)

6
negative Based on the 24 h
control and 8 compound
steatotic
compounds

Tetracycline and 0-0.1 mM of 0 and 14 d
amiodarone
tetracycline;
0-0.02 mM of
amiodarone
Bisphenol a

0.2 - 2000 21 d
nM

Stearic acid or 0 - 0.1 mM
Oleic acid with
insulin treatment

7d

Progression to (46)
NASH

↑TG and lipid-responsive NAFLD
genes; Stearic
acid
↑ Obesity
CYP2E1 activity

(46)

and (26)

Oleate: Palmitate 0.5 mM
(2:1); Palmitate
alone

48 h

Oleate: Palmitate 0.125 mM + 14 d or
(1:1) along with 10 ng/mL of 24 h
IL6
IL-6

Primary
Human Oleate: Palmitate 0.25 - 3 mM
Hepatocytes (PHH)
(2:1)

14 h
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3D spheroids from PHH

↑ Lipid accumulation; ↑TG; ↑
carnitine
metabolism;
Palmitate alone contributed ↑
insulin resistance; Palmitate
alone induced ↑ oxidative
stress;

O:P induced (48)
hepatic
steatosis;
Palmitate
induced
apoptosis and
progression to
NASH

IL-6 in 24 h ↓ CYP 1A2, 2A6, NAFLD
2B6, 2C19, 2C9, 3A4 and NASH
3A5 gene expression; O/P in
14 d ↓ CYP 1A2, 2A6, 2C19
gene expression
↓ CYP 1A2, 2A6, 2C9, 2D6, Hepatic
2E1 and 3A4 mRNA and Steatosis
enzyme activity

and (28)

(32)

Oleate: Palmitate 160 - 320 µM 48-72h
(1:1) with varying
concentration of
insulin, glucose
and fructose
Cryopreserved primary Oleate: Palmitate 0.6 mM
14 d
human
hepatocytes (2:1)
cultured into 3D model
using scaffolds and
maintained in LiverChip
platform

↑ Lipid accumulation; ↑TG NASH
accumulation with steatosis NAFLD
reversibility in absence of
FFA; insulin resistant
↓ CYP 3A4 and 2C9 enzyme NAFLD/
activity; ↑ Lipid accumulation; Steatosis
↑TG accumulation

(34)

Human
induced
pluripotent stem cellderived
hepatocytes
(hiPSC-Hep)

↑ Lipid accumulation; ↑TG Hepatic
accumulation
Steatosis

(8)

Oleate
and
Palmitate;
including inducer
for ER stress

50 - 200 µM 18 h
(Palmitate);
25
µM
Oleate

and (33)

Precision Cut Human Glucose
(G),
Liver Slices
Fructose
(F),
insulin (I) and
Palmitic
acid
(PA)
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Co-culture
Micro-patterned
coculture
(MPCC):
Primary
Human
hepatocytes plated in
collagen coated islands
along
with
3T3-J2
fibroblasts
Micro-patterned
coculture
(MPCC-HSC):
Primary
Human
hepatocytes plated in
collagen coated islands
along
with
hepatic
stellate cells (HSCs).
Tri-culture

Glucose

90K
HSC:30K
PHHs in 24 well
format

25 mM (G), 5 48 h
mM (F), 1
mM (I), 240
!M (PA)

↑ Lipid accumulation; ↑TG Hepatic
accumulation
Steatosis

(40)

0.5 mM - 25 10 d and 18 ↑ Albumin secretion; ↑ Urea Hepatic
(35)
mM
d
synthesis;
↑
lipid Steatosis and
accumulation; ↑ CYP3A4, T2DM
2A6, 2D6 mRNA and ↓
CYP2E1 mRNA; selective
insulin resistance.
14 d

↑ CYP3A4 and 2A6 activity; ↑ -albumin
secretion;
↑
distortion
of
hepatocyte
islands in 2 weeks.

(36)

31

Transwell
Insulin, glucose,
multiculture model:
Free Fatty Acids.
Nonparenchymal cells
(NPCs)
containing
stellate
and
macrophage (top of
transwell)
and
hepatocytes (bottom of
the
transwell)
incorporated
with
hepatic sinusoidal flow

Insulin (6.9 10 d
nM), glucose
(25
mM),
FFAs (65 μM
sodium
oleate and
45
μM
palmitic
acid).

↑Lipid Accumulation; ↑ De NASH
novo
lipogenesis
and
cholesterol synthesis; ↑ IL-8
and CK-18; and ↓ insulin
signaling

(37)

Micro-patterned
co- Glucose
culture (MPTC): Primary
Human
hepatocytes
plated
in
collagen
coated islands along
with 3T3-J2 fibroblasts
and hepatic stellate
cells (HSCs) in inserts.

5 mM

↑ Albumin secretion; ↑ Urea NASH/
synthesis;
↑
lipid fibrosis
accumulation; ↑ CYP3A4,
PXR, CAR mRNA and ↓
CYP3A4 and 2A6 enzyme
activity; ↓ NTCP, MRP2 and
BSEP mRNA; ↑ IL6 and C-RP
secretion
and
selective
insulin resistance.

(36)

Multi-cell culture

14 d

32

3D-human liver micro- Palmitate
tissues (InSphero): coculturing
primary
human
hepatocytes
with non-parenchymal
cells such as hepatic
stellate cells, Kupffer
cells and endothelial
cells
iPSCs
derived Oleate
organoids:
11 healthy and diseased
pluripotent stem cells
used in developing
reprogrammed
organoids composed of
the hepatocyte, stellate,
biliary-like
and
the
kuffer cells.

0.5 mM

9d

↑ IL8 imaging; ↑ pdgfr" gene NASH/
expression; ↑ TGFβ pathway; fibrosis
↑ Collagen deposition

(38)

0.8 mM

5d

↑ Lipid accumulation; ↑TG Steatosis/
accumulation;
↑IL6;
↑ inflammation/
hepatocyte ballooning; ↑ fibrosis
inflammation and fibrosis
associated genes; ↑ stiffness
associated with collagen
deposition

(39)
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Abstract
Background & Aim. Human hepatic carcinoma cell lines are commonly used in invitro
studies of lipid and xenobiotic metabolism, as well as glucose regulation in normal and
disease state. However, their validity is still under debate due to the variable expression
of proteins in the cell lines and human hepatocytes. In this present study, we used a data
independent acquisition based total protein approach (DIA-TPA) to quantify the protein
abundance in the different cell lines versus (vs.) human hepatocytes (cHH) and human
liver tissue (HLT). For this purpose, the global proteome from the whole cell homogenates
of HepaRG, HepG2, Huh7 cell lines were compared to cHH and HLT.
Methods. In-solution trypsin digestion of proteins in whole cell homogenate was conducted
using pressure-cycling technology (PCT). DIA was carried out by sequential window
acquisition of theoretical mass spectra (SWATH-MS). In addition, MS2 spectra for all
detectable peptides at its corresponding m/z were quantified using Spectronaut™, which
was then analyzed using TPA.
Results. In summary, 2715, 2578, 2874, 2717 and 3083 proteins in, HepaRG, HepG2,
Huh7, cHH and HLT, were identified at 1% FDR, respectively. The global proteome of the
cHH significantly differed from the cancer hepatic cell lines. Within the cell lines, the global
as well as ADME protein profile of HepaRG most closely correlated with cHH, with 84 out
of 101 ADME proteins, identified in HepaRG cells. Within gluconeogenesis and glycolysis
pathway, Huh7 cell line expressed proteins in high abundance in contrast to the other
groups.
Conclusion. In summary, the comparison demonstrates the capability of untargeted global
proteomics to detect the differences in protein expression among the different groups. In
addition, this study provides a comprehensive database of information to aid better study
design.
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1. Introduction
The human liver is the major organ for metabolism and clearance of xenobiotics,
maintenance of glucose homeostasis as well as regulation of lipid metabolism.1 Majority
of the circulating proteins in the plasma, such as albumin, that constitutes 55-70% of
human plasma is produced by the liver. Liver also play a central role in the excretion of
bile and cholesterol. The diverse metabolic and secretory function of the liver is aided by
the presence of specialized cell types such as hepatocytes, kupffer, stellate and biliary
endothelial cells. However, 80% of the tissue is comprised of the hepatocytes alone.2 The
hepatocytes are mostly binucleated3 and contains abundant proteins localized to
endoplasmic reticulum and mitochondria, indicating their effective role in protein synthesis
and energy metabolism, respectively.
In hepatocytes, the glucose consumption is observed via the uptake of plasma
glucose, followed by the break-down of the sugar moiety to pyruvate, which in-turn is
oxidized through the TCA cycle to produce ATP. Conversely, the glucose may also get
converted to fatty acids via de-novo lipogenesis pathways.4 On the other hand,
hepatocytes also play a critical role in lipid metabolism via conversion of non-esterified
fatty acids into tri-acylglycerols (TAG), which in-turn is stored or secreted as low-density
lipoproteins (VLDL) back into the plasma.4 Studies characterizing the mechanisms
involved in metabolic functioning of the liver, in the healthy as well as disease state such
as obesity, insulin resistance, non-alcoholic fatty liver disease (NAFLD) are on the
increase.5-8 The gold standard for such invitro studies are human hepatocytes. However,
the cost of procurement, donor-to-donor variability as well as limited availability renders
some disadvantages of using them for long-term studies. Consequently, hepatic
carcinoma cell lines such as HepG2, Huh7 and HepaRG cells are often used as an
alternative tool. In addition, immortalized hepatic cell lines have been routinely been used
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in toxicity as well as drug metabolism assays in preclinical studies.9-11 However, it is
unclear how well the tumor-derived cell lines represent the human hepatocytes in-context
to their protein expression involved in lipid and energy metabolism as well as xenobiotic
metabolism.
Shotgun proteomics is a powerful tool for analyzing proteolytic peptides of high
intensity, from low-throughput biological assays. The results generated are highthroughput and have a complete proteome coverage that out-weighs the traditional labor
and resource intensive western blotting techniques.2,12 Data-dependent acquisition (DDA)
has been used more commonly in untargeted analysis.13 However, bias associated with
the abundant peptides and the lack of sensitivity to quantify low-abundance proteins,
renders limitation to use this approach.14 Hence, sequential window acquisition of all
theoretical mass spectra (SWATH-MS) that follows a Data Independent Acquisition (DIA)
was employed to analyze the samples. Eventually, the DIA based total protein approach
(DIA-TPA) was used to compare the absolute protein levels of the human hepatocytes
and the carcinoma cell lines.15-17 This approach is sensitive to capture the low abundant
proteins which makes it ideal to compare the expression pattern of thousands of proteins
from the cell lines and human hepatocytes, at the same time. In addition, we compared
the protein expression from whole cell homogenate without enrichment. We believe this
novel approach of sample analysis overcomes the limitation of loss of proteins in
fractionation and enrichment and is more reflective of the biological state.2,18,19
The objective of this study was to compare the protein expression involved in the
glucose, lipid as drug metabolism pathways in immortalized hepatocyte cell-lines as well
as primary human hepatocytes. This comprehensive comparison provides a database to
aid the betterment of study design in the field of hepatology and pathophysiology.
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2. Materials and Methods
2.1. Chemical and Reagents
Trypsin digested β-galactosidase (E. coli) (Catalog No. #4445247) and TPCK-treated
trypsin (Catalog No. #4445250) was procured from Sciex (Framingham, MA). Bovine
serum albumin (BSA) (Catalog No. #23209) and Iodoacetamide (IAA) (Catalog No.
#I6125), Dithiothreitol (DTT) (Catalog No. #DTT-RO), Ammonium bicarbonate (Catalog
No. #40867) and Sodium deoxycholate (DOC) (Catalog No. #30970) were purchased from
Sigma-Aldrich (St. Louis, MO). MS grade acetonitrile (Catalog No. #A955), methanol
(Catalog No. #A456), choloroform (Catalog No. #C297) and formic acid (Catalog No.
#A117) were from Fisher-Scientific (Hampton, NH). Acquity UHPLC Peptide BEH C18
analytical column (Catalog No. #186005594) and VanGuard precolumn (Catalog No.
#186004629) were from Waters Corp. (Milford, MA).
2.2. Cell Culture
The cell lines and cHH were cultured as per conditions in-house or as per manufacturer’s
protocol. The conditions between the different cell lines and cHH were maintained as close
as possible with minor changes that conformed to specific cell lines and cHH.
Cryopreserved primary human hepatocytes (cHH). Three donors of cHH, namely lot,
LQG, AQL, VHB were obtained from Bio ReclamationIVT (Baltimore, MD) (Table 2.1) were
thawed in InVitro GRO CP media (Bio ReclamationIVT, Catalog No. #Z99029, Baltimore,
MD) and viable cells were counted using Tryphan-Blue (Sigma-Aldrich, Catalog No.
#T8154, St. Louis, MO) exclusion method. The cells were seeded in collagen coated 6well plate (Corning Inc., Catalog No. #354400, Corning, NY) at a seeding density of 0.7
million cells per well. After 4 h of plating, cells were washed and incubated using CP
media, to remove cell debris. Following 24 h of incubation at 37°C, cells were extracted
by gentle scraping using cell scraper (CELLTREAT Scientific Products, Catalog No.
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#229310, Pepperell, MA) in ice-cold DPBS (ThermoFisher Scientific, Catalog No.
#14040117, Waltham, MA) and 10-million cells from each lot was pooled for further
analysis. It was found that the cell attachment efficiency varied from donor to donor.
However, all lots were approximately 90% confluent before cell extraction.
HepG2 cells. HepG2 cells were purchased from American Type Culture Collection
(Manassas, VA). The HepG2 cells were cultured in Eagle’s Minimum Essential Media
(Sigma-Aldrich, Catalog No. #M2279, St. Louis, MO) supplemented with 10% FBS
(Sigma-Aldrich, Catalog No. #F2442, St. Louis, MO), 1% penicillin/streptomycin
(ThermoFisher Scientific, Catalog No. #15140122, Waltham, MA). Cell passage (6 & 7)
was performed with Trypsin-EDTA (ThermoFisher Scientific, Catalog No. #25200072,
Waltham, MA) when HepG2 cells were 80% confluent in culture. The cells were cultured
in 25 cm2 flask (Sigma-Aldrich, Catalog No. #CLS430639, St. Louis, MO) for 24h, before
subjected to cell extraction for proteomics analysis. Approximately 8-10 million cells were
cultured and harvested by cell scraping.
HuH7 cells. Huh7 cell line was kindly provided by Dr. Nisanne Ghonem (University of
Rhode Island). Cells were cultured in Dulbecco’s Modified Eagle Media (ThermoFisher
Scientific, Catalog No. #11320082, Waltham, MA) supplemented with FBS and 1%
penicillin/streptomycin. The concentration of FBS was maintained at 10% until cells
reached confluence. Upon confluence, cells were maintained for 3 weeks in 1% FBS.11
Cell passages (4 & 5) were performed with 0.25% trypsin-EDTA when cells reached 90%
conﬂuence in 25 cm2 flask. Approximately 8-10 million cells were cultured and harvested
by cell scraping.
HepaRG cells. Frozen undifferentiated HepaRG cells were purchased from Biopredic
International (Rennes, France). The cells were grown for 2 weeks in William’s E media
(ThermoFisher Scientific, Catalog No. #12551032, Waltham, MA), containing 1%
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glutamine (ThermoFisher Scientific, Catalog No. # A1286001, Waltham, MA), 1%
penicillin/streptomycin and 10% HepaRG growth supplement (Lonza Inc., Catalog No.
#ADD711C, Walkersville, MD) in 6-well plate. Following growth phase, cells were
differentiated in-house for 2 weeks in William’s E media, 1% glutamine, 1%
penicillin/streptomycin and 10% HepaRG differentiation supplement (Lonza Inc., Catalog
No. #ADD721C, Walkersville, MD) and maintained at 37°C with 21% O2 and 5% CO2
throughout the culture with media changed every 3 days. Upon differentiation, HepaRG
cells were cultured in basal media containing William’s E media, 100 U/mL penicillin, 100
µg/mL streptomycin, 2 mM glutamine, 5 µg/mL insulin (Sigma-Aldrich, Catalog No. #I-034,
St. Louis, MO) and 50 µM hydrocortisone hemisuccinate (Sigma-Aldrich, Catalog No.
#H2270, St. Louis, MO). Approximately 8-10 million cells were cultured and harvested by
cell scraping for proteomic analysis.
Human Liver Tissue. 100 mg of frozen human liver samples (n=3) from brain dead
donors were purchased from Sekisui XenoTech LLC (Kansas City, KS). The detailed
demographics of the donors are given in Table 2.1. Livers were graded by a
histopathologist as previously described20 and were categorized as normal, healthy livers.
2.3. Whole cell homogenate and proteomics sample preparation
An overview of the study workflow is given in Fig. 1. Cells scraped and collected in DPBS
was centrifuged at 300g at 4°C for 10 min. The cell pellets obtained was washed in DPBS
as mentioned above. Approximately 8-10 million cells from each group was pooled and
homogenized in 1000 µl of homogenization buffer (8 M urea, 50 mM Triethylammonium
bicarbonate, 10 mM DTT v/v) using a bead homogenizer (Omni Bead Ruptor 24,
Kennesaw, GA). In addition, 50 mg of liver tissue was homogenized in 1000 µl of
homogenization buffer, in similar fashion. Samples were then spun at 1,000 g for 5 min
and the supernatant was collected. The total protein concentration of the resulting sample
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was determined using Pierce BCA protein assay kit (ThermoFisher Scientific, Catalog No.
#23227, Waltham, MA).
2.4. In-solution trypsin digestion
Protein digestion was conducted as described previously with few adaptations.21,22
Samples (250 µg protein) were spiked with 2 µg of BSA and denatured with 25 µL of DTT
(100 mM) at 35°C for 30 min in a shaking water bath (100 rpm) (Precision Scientific,
Catalog No. #66800, Chicago, IL). After denaturation, samples were alkylated in the dark
with 25 µL of IAA (200 mM) for 30 min at room temperature. Samples were then
concentrated using the cold water, methanol and chloroform (1:2:1) precipitation method
(centrifugation at 10000 rpm, 5 min at 10°C) (Eppendorf, Catalog No. #5810 R, Hamburg,
Germany). The protein pellet was washed with ice-cold methanol and suspended in 100
µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v sodium deoxycholate
(DOC). Further, TPCK-treated trypsin (10 µg) was added to samples at a ratio of 1:25
(trypsin: protein) and samples were transferred into digestion tubes (PCT MicroTubes,
Pressure Biosciences Inc., Easton, MA). The barocycler was run at 35°C, for 75 cycles
with 60-sec pressure-cycle (50-sec high pressure, 10-sec ambient pressure, 25 kpsi).
Subsequently, 10 µg trypsin was again added to each sample and digestion was repeated
as mentioned above.
Furthermore, to 110 µL of digested peptides sample, 10 µL of acetonitrile (1:1, v/v
containing 5% formic acid) was added to precipitate DOC. Samples were spun (10,000
rpm for 5 min at 10°C) to remove the precipitate and 100 µL supernatant was collected.
Subsequently, 25 µL of the digested peptide sample was injected on the analytical column
and were analyzed using LC-MS/MS method described below.
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2.5. LC-MS/MS Analysis
Data-dependent analysis (DIA) was performed in positive ionization mode using a
DuoSpray™ ion source on a Sciex 5600 TripleTOF™ mass spectrometer (AB Sciex,
Concord, Canada) equipped with an Acquity UPLC HClass system (Waters Corp.,
Milford, MA, USA). Gas 1 (GS1), gas 2 (GS2) and curtain gas (CUR) were maintained at
55, 60 and 25 psi, respectively. Ion spray voltage floating (ISVF) was kept at 5500 V while
the source temperature (TEM) was 500°C. Declustering potential (DP), collision energy
(CE) and collision energy spread (CES) were set at 120, 10 and 5 respectively. During the
survey scan, all the ions with a charge state of 2 to 4, mass range of m/z 300-1250 and
exceeding 25 cps were used for MS/MS analysis. Former target ions were excluded for 8
sec and the mass tolerance for TOF-MS was 50 mDa with a 100 milliseconds
accumulation time. For product scan, data were acquired from 100 to 1250 m/z with an
accumulation time of 75 milliseconds with a total cycle time of 3.5 sec. Product ion analysis
was done under dynamic accumulation and rolling collision energy dependent on the m/z
of the ion.
Chromatographic separation was achieved over 180 min gradient method at 100 μL/min
on an Acquity UPLC Peptide BEH C18 (2.1 X 150 mm, 300 Å, 1.7 µm) preceded by an
Acquity VanGuard pre-column (2.1 X 5 mm, 300 Å, 1.7 µm). Mobile phase A was 98%
water, 2% acetonitrile, 0.1% formic acid and mobile phase B was 98% acetonitrile, 2%
water, 0.1% formic acid). Gradient conditions used were 98% A from 0 to 5 min, 98%
to 70% A from 5 to 155 min, 70% to 50% A from 155 to 160 min, 50% to 5% A from 160
to 170 min, 5% to 98% A held from 170 to 175 min. The gradient was held at initial
conditions from 175 min until the end of the run to equilibrate the column before the
start of next run. The flow was diverted to waste for the first 8 minutes and last 20 minutes
of the acquisition. Autosampler was maintained at 10°C, and the column was kept at
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50°C. Trypsin-digested β-galactosidase peptides were injected to monitor TOF detector
mass calibration every four samples.
2.6. SWATH-MS acquisition and data analysis
Homogenate samples were analyzed using SWATH-MS based spectra which were
acquired for mass range m/z 400−1100 Da within SWATH window width of 10 m/z
resulting in 70 overlapping mass windows per cycle, as described in the previous
literature21. The DIA data was searched against Swiss-Prot identifiers (October 2016) and
analyzed using Spectronaut™ Pulsar software (version 11.0, Biognosys AG, Schlieren,
Switzerland) was used to obtain MS2 signal intensities of fragment ions from DIA data
using default settings with a few modifications that includes specific trypsin/P digestion
with a minimum of 7 amino acids, maximum of 52 amino acids and 2 missed cleavages;
fixed modifications included carbamidomethyl (C) and variable modifications included
acetyl (protein N-terminus) and oxidation (M). Raw data files and search results are
available

at

Japan

Proteome

Standard

Repository

(jPOSTrepo

JPST000372,

ProteomeXchange PXD008593). The SWATH-MS DIA data was matched with the
reference spectral library generated from the DDA of pooled human liver samples using
Protein Pilot. The DIA data was then normalized and analyzed using “Total protein
approach” (TPA), as shown below (1).

… (1)
The absolute protein abundance of each group was represented as pmol/mg of protein.
2.7. Statistical and bioinformatic analysis
A number of normalization strategies were tested using NormalyserDE. LIMMA package
with multiple comparison was used to test for significance (FDR < 0.05, log2FC > 0.58 or
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log2FC <0.58) to identify differentially expressed proteins. Differentially expressed
pathways associated between human hepatocytes, and the three hepatocarcinoma cell
lines was assessed using ingenuity pathway analysis (Ingenuity Systems, Redwood City,
CA, USA). PCA analysis was conducted using Perseus (version 14.1, MKS Umetrics).
Hierarchical clustering was calculated using Euclidean distance metric was conducted
using Spectronaut™ Pulsar software. Venn diagram was drawn using an online tool
(http://bioinformatics.psb.ugent.be/webtools/Venn/). GraphPad Prism (version 8.0) was
used in data visualization and statistics. The Phase I, II and transporters protein
expression among the different groups were analyzed using one-way ANOVA and posthoc analysis of multiple comparison Bonferroni test was carried out to assess significance
(P<0.05).
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3. Results
3.1. Global proteome profile comparisons from DIA data among the whole cell lysate of
human hepatocytes, human liver tissue as well as the HepaRG, HepG2 and Huh7 cell
lines
As illustrated in the overall workflow (Fig. 2.1), DIA data was first generated from
the whole cell lysate samples of human hepatocytes (lot LQG, AQL, VHB), human liver
tissue (510, 758 and 791) and three hepatic cell lines, namely, the HepaRG, HepG2 and
Huh7. As a result, 2715, 2578, 2874, 2717 and 3083 proteins in, HepaRG, HepG2, Huh7,
cHH and HLT, were identified at 1% FDR, respectively (Table 2.2). It is to noted that, 153
(7.2%) proteins in HepaRG was found to be common with HLT and not with cHH (Fig.
2.2B), and we believe this is due to the bipotent progenitor status of HepaRG, resulting in
expression of hepatocyte-like and biliary-like cells.
In addition, the global proteome profiles of the cell lines, cHH and HLT were
analyzed using Perseus and represented as a PCA and heat map (Fig. 2.3B). Dramatic
differences were observed between cHH, HLT and the three cell lines. With regard to the
PCA analysis of component 1 and 2, it was noted that the HLT and cHH were grouped
closer to one another in comparison to the hepatic carcinoma cell lines. In addition,
hierarchical clustering (Fig. 2A) showed a similar pattern of the HLT and cHH grouped
together with minimum distance and hepatic carcinoma cell lines were clustered closer to
one another.
3.2. SWATH-MS analysis of ADME protein expression in the HLT, cHH and the hepatic
cell lines
To investigate the detection reliability, we performed label-free quantification on
both HLT and cHH (Fig. 2.4A). More than 2000 proteins were identified, of which 97%
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(2647 out of 2717) were found in both sample types. Overall, a good global correlation in
protein abundance of individual proteins were observed between the two sample sets. In
addition, we detected 89 out of the 101 ADME proteins (88%) chosen from the literature.
The ADME protein abundance, showed a good correlation around the line of unity.
The hepatic cell lines correlated moderately with the hepatocytes with 2309 (85%),
2174 (80%), 2308 (84%) of the global proteins from HepaRG, HepG2 and Huh7 matched
with 2717 proteins of cHH, respectively. Similarly, we detected 92 (91%), 70 (69%) and
74 (73%) out of the 101 ADME proteins, respectively. HepaRG, showed a more
comparable levels of ADME proteins (Fig. 2.4B), however Huh7 and HepG2 showed a
distribution of ADME proteins below the line of unity showing lower expression in these
cell lines in comparison to hepatocytes (Fig. 2.4C and D).
3.3. SWATH-MS analysis of proteins involved in energy and lipid metabolism in the HLT,
cHH and hepatic cell lines
Hepatocytes are pivotal in the energy supply and storage. The major pathways
such as glycolysis/gluconeogenesis, are involved in the conversion glucose to pyruvate,
eventually for ATP production (Fig. 2.5). Glucose undergoes phosphorylation by
hexokinase or glucokinase to form glucose-6-phosphate (G6P) that is converted to ATP
via glycolysis. Furthermore, via gluconeogenesis, pyruvate is converted to acetyl-CoA that
participates in ATP production as seen in TCA cycle. Alternatively, glucose is also used
up in lipid synthesis via pentose-phosphate pathway.
The protein expression in terms of energy metabolism varied significantly in HLT,
cHH and the hepatic cell lines (Fig. 2.6). For instance, the primary enzyme involved in
gluconeogenesis, 1,6-glucose bisphosphatase (FBP1/2), was identified only in cHH and
HLT. Other mitochondrial proteins involved in gluconeogenesis such as PCK2 and PC
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were found in higher abundance (~6 fold) in cHH than HepaRG cell lines. Hexokinase
(HK1), important enzymes involved in glycolysis was present in HLT, cHH and was
comparable to the levels in HepaRG cell line. In contrast, LDHA involved in the conversion
of lactate (released by the muscles) to glucose in hepatocytes was found in high
abundance in Huh7 cell lines (9-fold) in comparison to cHH (Fig. 2.6). There is some
evidence in literature, showing the ability of cancer cells to be reprogrammed to utilize
glycolysis at higher rates, in support to this we observed higher abundance of majority of
enzymes (ENO1, GAPDH, PGAM1, PGK1, PKLR, PKM, TPI1) in Huh7 cell line in
comparison to cHH (Table 2.3).23
The non-esterified fatty acids (NEFA) released from the adipocytes are taken up
by the hepatocytes and ligated to CoA that initiates the metabolism of fatty acids or triacyl
glyceride (TAG) synthesis. This process is carried out by different isoforms of ACSL,
namely 1,3 and 5. In cHH and HLT the most abundant form was noted to be ACSL1 and
the levels were comparable to HepaRG cell line. However, the isoform ACSL3 and ACSL5
play a predominant role in HepG2 cell line (Fig. 2.5). The fatty acids with more than 16
carbon chain may preferentially undergo peroxisomal oxidation. Enoyl-CoA Hydratase
and 3-Hydroxyacyl CoA Dehydrogenase (EHHADH), key enzyme involved in fatty acid
beta-oxidation was measured as 17.1 pmol/mg which was similar to HLT and 2-fold higher
than HepaRG (8.5 pmol/mg) cell line (Table. 2.4) Among the hepatic cell lines, HepaRG
cell line showed highest protein abundance of the groups of protein involved in both
peroxisomal and mitochondrial beta-oxidation in comparison to Huh7 and HepG2 cells
and was more comparable to cHH.
3.4. SWATH-MS analysis of proteins involved in xenobiotic transport and drug metabolism
Liver is the major organ that contributes to clearance and metabolism of drugs and
xenobiotics present in the circulation. This is accomplished by the specialized drug
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metabolizing enzymes present in the hepatocytes. The drugs in the circulations are taken
up by the hepatocytes via basolateral uptake transporters (Fig. 2.9A), followed by phase I
and/or phase II metabolism (Fig. 2.7 and 2.8), and eventually the metabolites are excreted
back into the blood or bile (Fig. 2.9B) to be eliminated by the kidney or the intestine,
respectively. In general, solute carrier (SLC) family facilitate uptake of xenobiotics from
the blood, while the efflux of compounds from hepatocytes are carried out by the ATPbinding cassette (ABC) family. It is to be noted, that our findings showed the most
abundant uptake transporters detected in cHH and HLT were organic anion transporter 2
(OAT2), organic anion transporting polypeptide 1B1 (OATP1B1), and OATP1B3 at around
4.0, 1.3 and 1.2 pmol/mg of total protein (Fig. 2.9A). OCT 7 as well as OATP1B1 and 2B1
were detected at within quantifiable limits in the HepaRG but not in HepG2 and Huh7.
Among the efflux transporters MRP6 was the most abundant followed by MRP2, BSEP
and MDR1.
The disposition of phase I and II metabolizing enzymes in cHH, HLT and the
hepatic cell lines is outlined in the Fig.2.7 and 2.8. Human hepatocytes expressed all
clinically relevant CYP450, such as, CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4 at 1-24
pmol/mg of total protein on an average, detected from the three lots of cHH. HepaRG cell
line, expressed some of these enzymes in comparable levels, namely, CYP2C19, 2D6,
3A4 and 3A5. In addition, CYP1A2, 2B6, 2C8 and 2C9 were detected at lower levels in
HepaRG than cHH. In comparison, HepG2 cell line did not express CYP1A2, 2B6, 2C8,
2C9, 2C19, 3A5 and 4A11 in detectable levels. In exception, to other CYPs, HepG2 cell
line was a high expresser for CYP2C19 (32.6 pmol/mg of whole cell lysate). Likewise, it
was interesting to note that Huh7 expressed CYP4A11, enzyme involved in fatty acid
metabolism, at levels higher than human hepatocytes. Amongst phase II metabolizing
enzymes, SULT1A1, 2A1 as well as UGT1A1, 1A3, 1A9, 2B15 were expressed at almost
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similar levels in the cHH as seen in HepaRG cells. However, majority of the phase II
enzymes detected in HepG2 and Huh7, were low abundance proteins (~1-2 pmol/mg of
total protein) in comparison to cHH.
3.5. Differentially regulated biological pathways in cell lines in comparison to human
hepatocytes.
IPA predicted the top 5 dysregulated pathways from the protein expression in each
group (HepaRG, HepG2, Huh7) vs. human hepatocytes with p value < 0.05 and log
FC>0.58 or <-0.58 (Fig. 2.10). It was to be noted that the biological pathways that was
perturbed was similar across the groups (Table 3.5). In addition, we also noted that the
predicted top upstream regulator that was significantly inhibited across all cell lines, was
found to be, HNF4α. We believe this probably contributes to the dysregulated protein
expression pattern seen in lipid and xenobiotic metabolism.
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4.

Discussion

Human hepatic carcinoma cell lines are commonly used in drug development to aid safety
assessment and for candidate selection for first-in-human (FIH) studies. Hence, there is a
need for well-characterized, fit-to-purpose, proliferative hepatic cell lines models, due to
the limited availability of primary human hepatocytes cells, inconsistency across donors
and variability in DMET expression.24 In addition, the need to understand hepatic-disease
state along with its impact on drug metabolizing enzymes propels the urgency for better
preclinical models of human origin. With this objective in mind, we screened HepaRG cells
as well as more traditional cell lines such as HepG2 and Huh7 for the expression of DME
and proteins involved in energy and lipid metabolism.6,7 HepaRG are cells derived from a
66 y old female patient with hepatocellular carcinoma.26 They are progenitor cells that
upon differentiation exhibit 50% hepatocyte-like and/or 50% biliary-like cell lineages.27 In
addition, upon differentiation, HepaRG cells are reported to express high levels of CYP450
and other Phase I and Phase II enzymes, that is confirmed using several micro array
studies.9,28,29 Apart from the reported gene expression data, very few reports discuss the
global proteome of these cell lines as well as the targeted DME protein expression. Also,
it is important to note that the known gene expression reports may not directly extrapolate
to its protein expression or its activity.30 Proteins being the functional unit of most biological
processes, it is critical to understand the protein expression profiles before choosing a
hepatic cell line to model drug metabolism or disease state.
To date, only a few proteomic studies have been reported in the literature
comparing the global proteomes of hepatic cell lines and human hepatocytes as well as
to quantify the DME protein expression. Some of the studies include contributions from:
Slany et al. wherein the proteome profiles of primary human hepatocytes were compared
to HepG2 and Hep3B using 2D-PAGE approach coupled with DDA based shortgun
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proteomics31; Xiaomei Gu and colleagues compared the proteomic characteristics of
HepG2, Hep3B2, H226, Ovcar3 and N87 using a TPA from Maxquant with DDA
approach13; Sison-young et al. compared HepG2, Upcyte and HepaRG to primary human
hepatocytes using a DDA strategy32; and recently Shi and colleagues used a DIA/SWATH
based approach to compare HepG2, Hep3B, and Huh7 to human hepatocytes.14 In most
cases, DDA based approach was used in analysis of proteomics signature. However, it
has limitations for the quantification of low abundant proteins. In contrast, DIA based
SWATH-MS approach is more sensitive and demonstrates high coverage, reproducibility
and precision for low abundant proteins. Hence, DIA based SWATH-MS approach is ideal
for measuring proteins in cell lines with low-to-moderate protein yield. Using the SWATHMS detection method we compared the global proteome expression, along with targeted
proteins involved in energy, lipid and xenobiotic metabolism among the cell lines and cHH
as well as HLT. Moreover, in contrast, to all the above-mentioned literature that employed
sub-cellular fractionation for enrichment, we analyzed the whole cell homogenate without
fractionation, to prevent the loss of proteins associated with fractionation, as well as the
variations associated with the scale-up of the fractionates. Henceforth, we believe, this
analysis will result in higher reproducibility and limit the batch-to-batch variability
associated with fractionation.
In the current study, a spectral library was generated from the DDA scans. A total
of <6000 proteins (combined) was identified using Protein Pilot at 1% FDR. However, not
all proteins were detected in all replicates. DIA based total protein approach (DIA-TPA)
was used to compare the global proteome among the different groups. We validated this
approach by comparing the values of DMET proteins reported in literature as pmol/mg of
total protein in wholes cell lysate. Wiśniewski et. al (2016) reported the protein levels from
human hepatocytes and HepG2 cell line using DDA based TPA approach. Our data
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closely matched with the published literature, despite the different stratergy (DIA-TPA)
involved in the analysis (Fig. 2.11-2.13).
Similar to the previous reports, dramatically different global proteome profiles were
observed between the cell lines and human hepatocytes (Figure 2.3, 2.4).14,32 However,
hepatic carcinoma cell lines most closely related to each other in comparison cHH and
HLT. Among the proteins expressed, the differentially regulated proteins as well as the
perturbed pathways among the different groups were analyzed using IPA (Qiagen,
Valencia, CA). As reported in the previous literature, the EIF2 signaling pathway, sirutin
and MTOR pathway along with biological oxidation were significantly dysregulated in
hepatic cell lines as opposed to human hepatocytes.14,32
Several DMEs were quantified in the cHH and HLT as well as the cell lines using
DIA based TPA approach. Among the 12 CYP450s quantified in cHH and HLT; 11 CYPs
were identified in HepaRG; 7 CYPs in Huh7 and 5 CYPs in HepG2 cell line. The
abundance of CYPs in HepaRG was more comparable to cHH than HepG2 and Huh7.
UGTs were highly expressed in cHH and HLT. In HepaRG cell line, 10 UGTs and 2 SULTs
were detected, however, UGTs (1A1, 1A3, 1A4 and 2B15) were not quantifiable in HepG2
and HuH7. Hence caution must be taken while choosing these cell lines for drug
metabolism related experiments. Having said that, it is also important to note that HepG2
cells expressed high levels of, MGST2 (2-fold), POR (2.5-fold), DHRS2 (360-fold) in
comparison to cHH. These enzymes have shown involvement in xenobiotic metabolism
as well as cancer. In contrast, Huh7 cells expressed GSTP1 (75-fold), AKR1C1 (0.7-fold),
ALDH1A1 (3-fold) and ADH5 (1.7 fold) in high abundance in comparison cHH (Appendix
I). Therefore, these cell lines can be a legitimate in vitro model when experiments are
tailored for targeted proteins of interest. 33,34
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With respect to the proteins involved in energy and lipid metabolism, we compared
a proteins involved in glycolysis, ß-oxidation and lipogenesis across different groups.
Majority of proteins involved in gluconeogenesis/glycolysis was expressed in high
abundance in Huh7 cell line (Figure 2.4B). Interestingly, the average expression across
the proteins involved in fatty acid metabolism was much higher in the HLT and cHH in
comparison to cell lines. HepaRG, expressed a general lower trend than cHH followed by
HepG2 and Huh7 cells. However, in contrast to the DME expression, the proteins involved
in lipid metabolism was highly expressed in the carcinoma cell lines, but not of the similar
abundance as human hepatocytes.
In conclusion, in this publication we used a DIA based TPA strategy to compare
proteome profiles of the whole cell homogenate of three hepatocarcinoma cell lines, i.e.
HepG2, Huh7 and HepaRG and compared it with cHH and HLT in the focus of proteins
associated to pathways of energy, lipid and xenobiotic metabolism. As discussed before,
we observed significantly different protein expression profiles among the groups in energy
and lipid metabolism as well as ADME protein expression. Therefore, caution must be
exercised when choosing the cell lines as in vitro models for drug metabolism or
developing models for disease states. This study provides a comprehensive database for
understanding the expression of proteins in different cell lines and we believe it will aid in
making informed choices for hepatic cell lines in future model development.
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5. Figures and Tables
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Figure 2.1: The figure illustrates the overall workflow of protein detection, identification and quantitation.

B

A

Figure 2.2: Venn diagram representing the overlapping number of proteins.
The figure shows the identified number of proteins in (A) human livers tissue, human
hepatocytes and the HepaRG, HepG2, and Huh7 cell lines and (B) HLT, Hepatocytes and
HepaRG alone, quantified by SWATH-MS. All proteins were identified in all three
replicates for each group. The diagram was produced using a web tool available at
http://bioinformatics.psb.ugent.be/webtools/C/. Abbreviation: HLT- Human liver Tissue.
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Figure 2.3: Heirarchial clustering of proteins differentially expression.
The figure (A) shows HLT, cHH, and the HepaRG, HepG2, and Huh7 cell lines (n= 3 for
each group) clustered together depending on Euclidean distance matrix. The 30 most
abundant proteins determined by DIA-TPA are represented in the heat map The MS2
signal intensity was presented as a Log2 value. White spots indicate zero intensity. The
figure (B) shows the grouping of cHLT, cHH and the HepaRG, HepG2, and Huh7 cell lines
generated from SWATH-MS based data.
Abbreviation: HLT – Human Liver Tissue; cHH – cryopreserved Human Hepatocytes;
SWATH-MS - Sequential Window Acquisition of theoretical Mass Spectra; DIA-TPA –
Data Independent Acquisition based Total Protein Approach.
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Figure 2.4: Correlation of protein abundances between the two groups.
(A) Human Hepatocytes vs. HLT (B) Human Hepatocytes vs. HepaRG (C) Human
Hepatocytes vs. HuH7 (D) Human Hepatocytes vs. HepG2. The global correlation in
protein expression indicated in grey and the correlation of ADME proteins in black. Dotted
lines indicate the line of unity.
Abbreviation: HLT – Human Liver Tissue.
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Figure 2.5: Heat map of the differential expression of protein involved in glucose
metabolism using SWATH-MS.
The protein expression is represented as the log2 fold change between the test group
(HLT, HepaRG, Huh7 and HepG2) vs. human hepatocytes. The figure shows proteins
involved in gluconeogenesis/glycolysis. X – not applicable when protein expression is
below limit of quantification. Abbreviation: HLT –Human liver tissue.
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Figure 2.6: Heat map of the differential expression of protein involved in lipid
metabolism using SWATH-MS.
The protein expression is represented as the log2 fold change between the test group
(HLT, HepaRG, Huh7 and HepG2) vs. human hepatocytes. The figure shows proteins
involved in lipid metabolism. X – not applicable when protein expression is below limit of
quantification. Abbreviation: HLT –Human liver tissue; FA – Fatty acid.

66

CYP450 Enzymes
*
**

CYP4F2

ND

*

CYP4A11

cHH
HLT
HepaRG
Huh7
HepG2

ND

CYP3A5
ND

CYP3A4
CYP2J2

ND

ND
ND
ND

***

CYP2E1
CYP2D6
CYP2C19
CYP2C9
ND

**

CYP2C8

ND
ND

CYP2B6
ND

CYP1A2

pmol/mg of cell homogenate protein

0
10

10

1

0.

1

ND

Figure 2.7: Cytochrome P450 expressing profile from SWATH-MS.
The significance was assessed using one-way ANOVA with multiple comparison
Bonferroni test * denotes p <0.05; ** denotes p <0.01; *** p<0.001. ND stands for not
determined due to low expression. The proteins were expressed as the average of
triplicates in pmol/mg of total protein. Error bars represent SD. Abbreviations: CYP cytochrome.
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Figure 2.8: Drug metabolizing enzymes involved in phase II.
The significance was assessed using one-way ANOVA with multiple comparison
Bonferroni test * denotes p <0.05; ** denotes p <0.01; *** p<0.001. ND stands for not
determined due to low expression. The proteins were expressed as the average of
triplicates in pmol/mg of total protein. Error bars represent SD. Abbreviations: UGT UDP-glucuronosyltransferase; SULT – sulfotransferase.
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Uptake Transporters

OATP2B1

OATP1B3

OATP1B1

cHH
HLT
HepaRG
Huh7
HepG2

ND
ND

ND
ND
ND

cHH

Efflux Transporters

HLT
HepaRG
Huh7
HepG2

MRP2

BSEP

*

ND
ND

ND
ND

MDR1

OAT7
MRP6

ND

***

OAT2

**

*

ND
ND

MRP3

ND

0.

1

10

ND

pmol/mg of cell homogenate proteins

1

ND

1

1
0.

**

OCT3

pmol/mg of cell homogenate proteins

Figure 2.9: Xenobiotic transporters quantified using SWATH-MS.
The significance was assessed using one-way ANOVA with multiple comparison
Bonferroni test * denotes p <0.05; ** denotes p <0.01; *** p<0.001. ND stands for not
determined due to low expression. The proteins were expressed as the average of
triplicates in pmol/mg of total protein. (A) uptake transporters (B) efflux transporters.
Error bars represent SD.
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C

B

A

70

HepaRG vs. Hepatocytes

HepG2 vs. Hepatocytes

HuH7 vs. Hepatocytes

Figure 2. 10: Volcano plots representing number of differentially expressed proteins in HepaRG, HepG2 and Huh7 in
comparison to Human Hepatocytes.
Dots in blue represent the differentially expressed proteins based on FDR < 0.05 and log2FC <0.58 or log2FC >0.58 in (A) HepaRG
(B) HepG2 (C) HepaRG in comparison to human hepatocytes.

Figure 2.11: Comparison of P450 protein using SWATH-MS DIA-TPA data with
published data (Weisnewski et. al, 2016) based on DDA-TPA approach.
The square in black represent the average of human hepatocytes (n=6) enzymes with min
and max range. The triangle represents the average of human hepatocytes from current
study.
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Figure 2.12: Comparison of UGT proteins using SWATH-MS DIA-TPA data with
published data (Weisnewski et. al, 2016) based on DDA-TPA approach.
The square in black represent the average of human hepatocytes (n=6) enzymes with min
and max range. The triangle represents the average of human hepatocytes from current
study.
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Figure 2.13: Comparison of transport proteins using SWATH-MS DIA-TPA data with
published data (Weisnewski et. al, 2016) based on DDA-TPA approach.
The square in black represent the average of human hepatocytes (n=6) enzymes with min
and max range. The triangle represents the average of human hepatocytes from current
study.
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Table 2.1: Demographic information of the cryopreserved human hepatocytes.
Product #

Lot #

Yield
Viability (million
cells)

Age
(years)

Race

Sex

BMI

M00995-P

LQG

81%

8.98

32

WH

M

23.5

M00995-P

AQL

91%

8.34

63

WH

M

26.1

F00995-P

VHB

86%

8.30

57

WH

F

26.4
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Table 2.2: Global hepatic protein in HepaRG, HepG2, Huh7 cell lines and human hepatocytes identified using Spectronaut

Precursor
Peptides

75

Human Hepatocytes
1
2
3
3476 3612 3614
0
7
8
2479 2549 2563
1
9
0
2966 3028 3043

Proteins
Proteins
represente
2717
d in all
replicates

Human Liver Tissue
1
2
3
4391 3212 4615
4
0
6
3004 3146 3141
0
0
2
3335 3382 3,371

HepaRG
1
2
2965 3357
6
7
2248 2504
9
1
2904 3132

3083

2715

3
3240
0
2428
3
3057

HepG2
1
2499
5
1948
6
2808
2578

2
2781
8
2142
3
2967

3
2895
2
2197
8
2990

Huh7
1
3383
1
2547
4
3249
2874

2
3276
0
2472
6
3203

3
3063
5
2327
7
3088

Table 2.3: The proteins expressed in gluconeogenesis/glycolysis detected using SWATH-MS.
The average of the triplicates is tabulated and expressed in pmol/mg of protein. NA denote the protein expression below detectable
limits.
Gene
Name

Location

ALDOA

Cytoplasm

ENO1

Mitochondrion

FBP1
FBP2

Cytoplasm
Cytoplasm
Cytoplasm

G6PC

76

GAPDH

Nucleus,
cytoskeleton
cytosol

GPI

Cytoplasm

Function
Gluconeogenesis/
Glycolytic process
Cell membrane, cytoplasm
and nucleus
Gluconeogenesis
Gluconeogenesis

and

cHH
HLT
HepaRG
HepG2
Huh7
(pmol/ mg of (pmol/ mg (pmol/ mg (pmol/ mg (pmol/ mg
protein)
of protein) of protein)
of protein) of protein)
1.2

5.2

15.0

40.5

25.4

13.6

60.8

87.1

145.2

55.2

5.7
2.4

26.3
19.0

NA
NA

NA
NA

NA
NA

Gluconeogenesis

1.1

0.9

0.3

NA

0.7

Gluconeogenesis/
Glycolytic process

89.7

224.2

155.2

432.2

71.2

Glycolysis

1.1

6.9

6.8

7.6

2.0

Glycolysis

5.2

2.5

2.2

0.8

1.0

Pyruvate metabolism
Pyruvate metabolism
Gluconeogenesis
Gluconeogenesis
Gluconeogenesis

38.0
1.0
20.7
1.8
84.5

204.8
2.6
14.6
2.8
21.5

175.8
NA
3.2
16.9
13.8

351.6
0.6
2.7
NA
3.3

122.3
NA
3.0
0.3
17.7

LDHA
LDHB
PC
PCK1
PCK2

Mitochondrion
membrane protein
Cytoplasm
Cytoplasm
Mitochondria
Cytoplasm
Mitochondria

PFKL

Cytoplasm

Glycolysis

0.7

1.5

0.4

1.5

0.5

PGAM1
PGK1

Nucleus
Cytosol

Glycolysis
Glycolysis

4.3
6.9

20.8
28.0

13.4
36.7

43.3
66.6

5.7
14.5

HK1

PKLR

Cytosol

Glycolysis

4.2

6.9

32.0

80.9

12.0

PKM
TPI1

Nucleus
Cytoplasm

Glycolysis
Gluconeogenesis

1.6
14.6

2.3
64.0

72.9
25.1

173.7
126.2

22.8
22.5
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Table 2.4: The proteins expressed in lipid metabolism detected using SWATH-MS.
The average of the triplicates is tabulated and expressed in pmol/mg of protein. NA - Protein expression below detectable limits.
Gene
Name

ACSL1
ACSL3
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ACSL5
ACAA1
ACOX1
ACOX2
ACOX3

Location

Peroxisome,
ER and mitochondria
Peroxisome,
ER and mitochondria
Peroxisome,
ER and mitochondria
Peroxisome
Peroxisome

Peroxisome
Peroxisome
Peroxisome
EHHADH
HSD17B4 Peroxisome
Mitochondria
CPT1A
CPT2
Mitochondria
SLC25A20 Mitochondria
Mitochondria
ACAA2
Mitochondria
ACADL
ACADM
Mitochondria
Mitochondria
ACADS
Mitochondria
ACADSB
Mitochondria
ACADVL
Mitochondria
ECHDC1
Mitochondria
ECHDC2

Function

Acyl-CoA Ligase
Acyl-CoA Ligase
Acyl-CoA Ligase
Peroxisomal !-oxidation
Peroxisomal !-oxidation
Peroxisomal !-oxidation
Peroxisomal !-oxidation
Peroxisomal !-oxidation
Peroxisomal !-oxidation
Carnitine Shuttle
Carnitine Shuttle
Carnitine Shuttle
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation

cHH
HLT
HepaRG
HepG2
Huh7
(pmol/ mg (pmol/ mg (pmol/ mg (pmol/ mg (pmol/
of protein) of protein) of protein) of protein) mg of
protein)
38.2

35.3

27.6

0.4

1.0

0.8

1.8

3.4

6.1

11.1

7.7
47.2
3.2
7.4
0.7

6.5
24.5
1.9
3.5
0.6

6.3
15.3
1.6
0.8
0.7

3.9
9.6
1.2
0.9
0.4

15.3
4.4
1.5
0.8
0.3

17.1
57.7
1.6
6.6
9.8
125.6

10.8
42.6
1.4
6.6
4.9
79.3

8.5
34.8
1.6
4.5
4.4
30.7

0.6
10.6
0.5
1.5
2.0
7.2

0.8
12.9
2.3
1.5
1.6
7.8

1.0
28.3
16.1

0.4
20.4
13.4

1.5
13.5
0.9

NA
2.8
1.0

NA
5.3
2.2

20.6
9.8
1.4
27.0

12.4
10.9
2.6
14.2

2.8
10.7
1.9
1.4

2.1
3.2
0.9
NA

9.9
2.8
1.4
NA

ECHDC3
ECHS1
HADH
HADHA
HADHB

Mitochondria
Mitochondria
Mitochondria
Mitochondria
Mitochondria

Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation
Mitochondrial !-oxidation

8.5
181.5
48.6
28.4
15.4

3.8
110.4
40.4
23.4
12.6

9.3
35.2
23.1
20.4
12.6

0.8
17.9
5.2
6.9
3.4

NA
13.5
9.5
17.6
10.4
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Table 2.5: Top 5 differentially regulated pathway in HepaRG, Huh7, HepG2 when compared to human hepatocytes.
R HepaRG vs. Human Hepatocytes
a
#Entitie #Entitie pVal
n Pathway
s found s total
ue
k name

HuH7 vs. Human Hepatocytes

HepG2 vs. Human Hepatocytes

Pathway
name

#Entitie
s found

#Entities pVal
total
ue

Pathway
name

#Entitie
s found

#Entitie
s total

pVal
ue

1

EIF2
Signaling

125

224

EIF2
Signaling

106

224

7.19
E-66

157

2.16
E-28

75

292

7.26
E-26

54

171

1.36
E-23

59

210

9.59
E-23

EIF2
Signaling

99

3

Remodeli
ng
of
Epithelial
34
Adherens
Junctions

80

2

Regulatio
n of eIF4
and
59
p70S6K
Signaling

224

157

69

mTOR
Signaling
4

5

58

Sirtuin
Signaling
Pathway

69

3.94E
-55

1.21E
-28

1.19E
-21

Mitochon
drial
Dysfuncti
on

87

Oxidative
Phosphor
ylation
66

210

1.79E
-20

Regulatio
n of eIF4
and
78
p70S6K
Signaling

292

5.79E
-20

Sirtuin
Signaling
Pathway

95

171

109

1.14E
-78

1.83E
-50

4.30E
-45

157

2.35E
-44

292

8.47E
-35

Regulation
of eIF4 and
p70S6K
57
Signaling
Sirtuin
Signaling
Pathway

Mitochondr
ial
Dysfunctio
n
mTOR
Signaling
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Abstract
Background & Aims. Hepatic lipid accumulation (steatosis) is an early sign of a spectrum
of Non-alcoholic Fatty Liver Disease (NAFLD) that precedes fibrosis and cirrhosis. To
manage NAFLD and related co-morbidities, patients are administered an array of
pharmacological agents.

Therefore, understanding of the effect of NAFLD on drug

disposition is warranted. Using a HepaRG model, we aimed to mimic steatosis in vitro,
and to examine its effects on drug-metabolizing enzymes (DME) and transporters.
Methods. HepaRG cells, differentiated in-house, were exposed to a mixture of saturated
and unsaturated fatty acids (1:2 ratio of 0.5 mM palmitate and oleate complex conjugated
to BSA for 72h) and were subjected to RNA sequencing and proteomic analyses. Lipid
accumulation was ascertained by Oil Red O (ORO) staining and triglyceride (TG)
quantitation and cell viability by WST-1 determination.
Results. The treatment condition resulted in ~6-fold increase in TG concentration without
reducing cell viability. RNA sequencing and Proteomics (SWATH-MS) of lipid-loaded and
control cells identified a total of 393 differentially expressed transcripts (89 up- and 304
down-regulated) and

127

downregulated), respectively.

differentially

expressed proteins

(127

up- and 38

Moreover, lipid loading resulted in significant down-

regulation of mRNA transcripts of transcription factors, NR1I2 (-1.18) and HNF4α (-0.55),
phase 1 DMEs including CYP1A2 (-3.25), 2B6 (-2.02), 2C8 (-1.48), 2C9 (-2.00),2C19 (1.32) and 3A4 (-1.87), phase 2 DMEs including UGT1A6 (-0.36) and 2B7 (-1.09),
SULT2A1 (-0.75) and 1E1 (-1.41) as well as clinically relevant transporters such as
ABCC11 (-1.36), ABCG5 (-1.66), SLC10A1(-1.63), SLCO2B1(-1.49) and SLC10A1 (1.63). Furthermore, lipid loaded cells significantly upregulated AKR1B10 mRNA (2.17)
and protein (0.99) that may regulate lipid as well as xenobiotic metabolism.
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Conclusion. Expression of several DME and transporter mRNA was altered in an in vitro
model of hepatic steatosis which may translate to altered drug disposition in NAFLD
patients.

Keywords
Hepatic steatosis, Non-alcoholic Fatty Liver Disease, Cytochrome P450, DrugMetabolizing Enzymes, Transporters, HepaRG.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the United States as
well as other developed counties (Bellentani, 2017). Excess intake of calories and lack of
physical activity can cause accumulation of free fatty acids (FAF) and triglyceride (TG) in
hepatocytes leading to the development of steatosis (Veteläinen et al., 2007). NAFLD
which is associated with metabolic syndrome, includes a spectrum of liver disorders,
initiating with simple steatosis, progressing to nonalcoholic steatohepatitis (NASH) and
possibly lead to end-stage cirrhosis (Koo, 2013; Cobbina and Akhlaghi, 2017).
Furthermore, patients with steatosis are at a greater risk of developing hepatocellular
carcinoma (HCC) (Ohata et al., 2003). The benign nature of steatosis is considered as
the "first hit" in the progression of NAFLD. The "second-hit" is manifested via reactive
oxygen species (ROS) induced stress, which leads to the infiltration of inflammatory
factors, hepatocellular ballooning and deposition of collagen fibers in hepatocytes as
observed in NASH and fibrosis (Caldwell and Argo, 2010).
Approximately 29% of the patients diagnosed with NASH will develop cirrhosis later in
life (Cohen, Horton and Hobbs, 2011). Currently, many pharmaceutical companies are
aspiring to develop medications for the treatment of NAFLD (Noureddin, Zhang and
Loomba, 2016; Brodosi et al., 2016). Moreover, considering that NAFLD is associated with
other co-morbidities including diabetes (Brunt and Tiniakos, 2010), patients are
administered several other medications and are at a greater risk of adverse drug reactions.
Recently, it was shown that the ADME (Absorption, Distribution, Metabolism and
Excretion) properties of midazolam and morphine is altered in NAFLD or NASH (Jamwal
et al., 2018; Farrow and Facchini, 2013). Hence, a comprehensive understanding of the
differential expression of Drug-Metabolizing Enzyme and Transporters (DMET) in NAFLD
is warranted to predict the PK properties of pharmaceutical agents.
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To study steatosis, it is crucial to identify an appropriate disease model. Significant
differences exist in the manifestation of this disease between humans and rodents. Dietinduced mouse models fail to recapitulate the full spectrum of NAFLD manifestation in
human (Gómez-Lechón, Jover and Donato, 2009; Merrell and Cherrington, 2011).
Feeding high-fat diet (HFD) to mice generate simple steatosis; however, male C57BL/6
mice fail to progress to NASH even in the presence of a high fructose-rich diet (Takahashi,
Soejima and Fukusato, 2012). Whereas, a methionine-choline-deficient (MCD) diet
induces a phenotype of severe NASH without metabolic syndrome and obesity features
16

. In addition, genetically modified mouse models including ob/ob or db/db often fail to

recapitulate the full spectrum of the disease (Larter and Yeh, 2008). Collectively, the
disparity between rodent models and human with respect to the regulation and tissue
distribution of DMETs (Prueksaritanont, 2010) (Martignoni, Groothuis and de Kanter,
2006) limit the usefulness of data obtained from animal models of NAFLD/NASH.
Use of primary human hepatocytes (PHH) or cryopreserved hepatocytes is considered
the gold standard for studying DMET in vitro (Lecluyse and Alexandre, 2010). In addition,
FA-loading has been previously attempted with primary human and rat hepatocytes using
static and dynamic chip-based systems (Donato et al., 2006; Kostrzewski et al., 2017;
Bulutoglu et al., 2019). However, the availability of early-stage biopsy samples, donor-todonor variability, cost involved in model development and limited time in culture before the
onset of dedifferentiation diminishes the utility of PHH as an effective tool for disease
model development. In this regard, the HepaRG cell line is a promising in vitro model
presenting a more robust DMET gene expression pattern than HepG2 and Huh7 cell lines
(Gerets et al., 2012). HepaRG cells are an immortalized human hepatocellular carcinoma
cell line comprised of a mixture of both hepatocyte-like and biliary-like cells (Guillouzo et
al., 2007).

Furthermore, they preserve their phenotype for over 2 weeks upon
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differentiation (Aninat et al., 2006). These attributes make HepaRG cells a suitable cell
line for the development of a disease model and its utilization for studying therapeutic
modalities.
We aim to characterize the molecular basis of NAFLD using a HepaRG model aiming
to understand the regulation of DMET in the disease state. Steatosis was induced by
treating HepaRG cells with a mixture of saturated and unsaturated fatty acids (FA). To
obtain steatotic global gene expression profiles, we carried out RNA sequencing (RNASeq) on HepaRG cells treated with FA or control. Subsequently, the proteomics signature,
altered activity of cytochrome P450 (CYP) 3A4 and CYP2E1 were recorded in this model
of steatosis.
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2. Material and Methods
2.1 Cell Culture Model
HepaRG cells were purchased from Biopredic International (through licensing
agreement from Inserm, France) and were grown and differentiated in-house according to
manufacturer's instructions. The incubation was carried out in a at 37 °C with 5% CO2
(New Brunswick Galaxy® incubator CO2, Model# 170R, New Brunswick, NJ). Following
14 days growth and 14 days differentiation phases, the cells were seeded in a 24 well
plate, and were treated with basal medium containing Williams E with Glutamax-I, 100
IU/ml of penicillin, 100 μg/ml of streptomycin, 4 μg/ml of bovine insulin and 5 × 10−5 M of
hydrocortisone hemisuccinate for 5 days.
To induce steatosis, HepaRG cells were treated with FA (1:2 palmitate: oleate)
conjugated to 30% essentially fatty acid-free (FAF) BSA solution (Sigma-Aldrich, Catalog#
A9576, Saint Louis, MO) made up in Williams E media (Thermo-Fisher Scientific, Catalog#
12551-032, Waltham, MA). The control cells were treated with 30% essentially FAF BSA
solution alone. The cells were treated for 24h, 48h and 72h with media replenished after
48h (Brown et al., 2013).
2.2 Oil Red O Staining
HepaRG cells treated with 0.5 mM FA or control for 24h, 48h and 72h. Cells were
washed twice with 1X PBS and fixed with 4% paraformaldehyde (Sigma-Aldrich, Catalog#
100496, Saint Louis, MO) for 30 min in room temperature (RT). Following this, 500 µl of
working Oil Red O (ORO) solution (3 parts of stock ORO and 2 parts of dH2O) (SigmaAldrich, Catalog# O0625, Saint Louis, MO) was added and incubated at RT for 20 min.
The cells were washed 3X with distilled water (dH2O), and 500 µL of hematoxylin (SigmaAldrich, Catalog# H3136, Saint Louis, MO) was added for 1 min to stain the nuclei and
their image was obtained using EVOS cells imaging systems (Life Technologies, Model#
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M7000, Foster City, CA). The extent of neutral lipid accumulation was quantified after
extraction in 100% isopropanol, and the absorbance was measured at 492 nm using a
SpectraMax plate reader (Molecular Devices, Model# M2, Sunnyvale, CA).
2.3 WST-1 cell viability
Cells were treated with 0.1-2 mM BSA conjugated with FA (1:2 palmitate: oleate)
for 72h in a 96 well format. The positive control used for this experiment was clotrimazole
(100 µM).

Following treatment, WST-1 reagent (Roche Diagnostics, Catalog#

11644807001, Mannheim, Germany) was diluted 100X times in HepaRG basal media.
The media was added to cells and incubated in 37 °C for 4h. The supernatant was
collected and analyzed using the SpectraMax M2 plate reader at 440 and 600 nm
wavelengths.
2.4 TG Accumulation
Approximately 10 million cells (HepaRG control vs. FA) were rinsed with PBS and
scraped off the flask using a rubber policeman cell scraper. Cells were resuspended in
PBS and lysed by sonication twenty times with one-second bursts. The samples were
centrifuged at 10,000 xg for 10 minutes at 4 °C, and the supernatant was collected and
assayed for TG content using a TG colorimetric assay kit (Cayman Chemicals, Catalog#
10010303, Ann Arbor, MI) according to manufacturer's protocol. The optical density was
read at 540nm on SpectraMax M2 plate reader.
2.5 Cholesterol Assay
One million HepaRG cells (0.5 mM FA treatment vs. control) were trypsinized, and
cell pellets were lysed with 200 μL of chloroform: isopropanol: NP-40 (7:11:0.1) in a microhomogenizer. The cell lysate was centrifuged at 15,000 x g for 10 min. The supernatant
was isolated and air dried at 50 °C to remove the chloroform. Samples were placed in a
vacuum for 30 minutes to remove the trace amounts of organic solvent. Dried lipids were
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mixed in 200 μL of 1X assay diluent with sonication and vortex mixed until dissolved. The
extracted samples were assayed using a total cholesterol calorimetric assay kit (Cell
Biolabs Inc., Catalog# STA-384, San Diego, CA).
2.6 Assessment of Oxidative Stress
Differentiated HepaRG cells (10 million cells) were treated with BSA or FA
treatment (0.5 mM) for 72 hours in triplicates. Oxidative stress was analyzed as a measure
of lipid peroxidation to Malondialdehyde (MDA). The samples were quantified using
OxiSelect™ TBARS Assay Kit (Cell Biolabs Inc., Catalog# STA-330, San Diego, CA).
Following this, samples were analyzed at 542 nm using SpectraMax M2 plate reader.
2.7 Insulin-stimulated phosphorylation of Protein Kinase B (Akt)
Following 72h of FA treatment, HepaRG cells were placed in serum-free EMEM
media for 12 h followed by stimulation with recombinant human insulin (Sigma-Aldrich,
Catalog# 1376497001, Saint Louis, MO) at 1, 10 or 100 nM for 10 min at 37 °C. Samples
were rinsed in PBS and lysed with RIPA buffer (150mM NaCl, 50mM Tris, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS, 1mM EDTA) supplemented with a complete
protease inhibitor cocktail (Sigma-Aldrich, Catalog# CO-RO, Saint Louis, MO) and Halt
Protease Inhibitor Cocktail (Thermo Fisher Scientific, Catalog# 78430, Waltham, MA) for
30 min at 4 °C. The lysate was run on a sandwich ELISA kit that detects both pAkt
(Ser473) and total Akt (Abcam, Catalog#126433, Cambridge, MA).

The assay was

performed according to manufacturer's protocol and the results were expressed as a ratio
of phospho-Akt to total Akt.
2.8 RNA extraction and sequencing
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA) from
differentiated HepaRG cells (1 million cells per well) plated in a 6-well plate (0.5 mM FA
treatment vs. control for 72h). The contents of each well were considered as a replicate
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for RNA extraction and subsequent sequencing. The ratio of absorbance at 260 nm and
280 nm was used to assess the purity of RNA using Nanodrop (Thermo Fisher Scientific,
Catalog #ND-ONE-W, Waltham, MA). Samples with a 260/280 ratio of ~1.8 and RNA
Integrity Number (RIN) > 8 were selected for further analysis. RNA integrity and quantity
were measured using Agilent 2100 Bioanalyzer System (Agilent Technologies, Santa
Clara, CA). Total RNA input for library preparation was assessed using the Qubit RNA
BR assay (ThermoFisher Scientific catalog# Q10210). RNA sequencing was performed
on 100ng of oligo(dT) purified poly(A)+ mRNA. A standard TruSeq mRNA library was
constructed using TruSeq® Stranded mRNA NeoPrep™ Kit v2 (Illumina, Catalog # NP202-1001, San Diego, CA). The library was sequenced by Illumina NextSeq 500 using a
paired-end run (2×75 bases).

The fastq files were generated using BaseSpace via

bcl2fastq.
2.9

RNA-seq data analysis

Sequencing data have been uploaded in the Gene Expression Omnibus (GEO) database
that can be viewed with the accession number of GSE122151. The data analysis and
visualization were carried out using QuickRNASeq, an integrated pipeline used in the
analysis for large-scale RNA-Seq data (Zhao et al., 2016). Read mapping and counting
was performed using STAR and featureCounts. Following this, RSeQC package was
included to employ all the QC metrics and to remove outliers; whereas VarScan, platformindependent software tool was included for variant detection in RNA-Seq data.

A

generalized linear model was used instead of a pairwise comparison approach to account
for the changes between treatment and control according to the R user’s guide to
determine differentially expressed genes. We used log2 FC > 0.58 as a cut-off combined
with exclusion criteria with False Discovery Rate (FDR) < 0.01 and p-value < 0.05, to
define the differentially expressed genes.
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2.10 SWATH-MS acquisition and data analysis
Cell homogenate samples were analyzed using SWATH-MS based spectra which
were acquired for mass range m/z 400−1100 Da within SWATH window width of 10 m/z
resulting in 70 overlapping mass windows per cycle, as described in the previous literature
(Jamwal et al., 2017). The DIA data was searched against Swiss-Prot identifiers (October
2016) and analyzed using Spectronaut™ Pulsar software (version 11.0, Biognosys AG,
Schlieren, Switzerland) was used to obtain MS2 signal intensities of fragment ions from
DIA data using default settings with a few modifications that includes specific trypsin/P
digestion with a minimum of 7 amino acids, maximum of 52 amino acids and 2 missed
cleavages; fixed modifications included carbamidomethyl (C) and variable modifications
included acetyl (protein N-terminus) and oxidation (M). Raw data files and search results
are available at Japan Proteome Standard Repository (jPOSTrepo JPST000372,
ProteomeXchange PXD008593). The SWATH-MS DIA data was matched with the
reference spectral library generated from the DDA of pooled human liver samples using
Protein Pilot. The DIA data was then normalized and analyzed using “Total protein
approach” (TPA), as shown below (1).

…(1)
The absolute protein abundance of each group was represented as pmol/mg of protein.
2.11 Gene Expression Validation
Real-Time PCR. Real-time PCR for human CYP mRNA levels was performed using a
ViiA7 Instrument (Thermo Fisher Scientific, Catalog # 4453534, Waltham, MA) and
TaqMan

assays

(Hs00559367);

used
NR1l3

are

as

follows:

CYP3A4

(Hs00901571_m1);
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NR1l2

(Hs00604506_m1);
(Hs01114267);

CYP2E1
GAPDH

(Hs99999905_m1); 18 S (4332641); and β-actin (Hs99999903) (Thermo Fisher Scientific,
Waltham, MA). GAPDH, 18 S rRNA and β-actin were used as housekeeping gene controls
to normalize the data. The reaction mixture (20 μl/well) contained 30 ng of cDNA (2 μl),
10× Taqman Universal Master Mix (10 μl), Taqman primers (1 μl) and RNase free water
(7 μl). The thermal cycle conditions were identical for all the genes analyzed. The qPCR
steps include 50 °C for 2 min followed by denaturation at 95 °C for 10 min, 40 cycles of
95 °C for 15 s and 60 °C for 1 min. Fold change was calculated by the formula: Fold =
2−ΔΔCt, where ΔCt represents the difference in cycle threshold number between the target
gene and the housekeeping gene, whereas ΔΔCt represents the difference between
control and fatty acid treatment groups. mRNA samples from individual wells treated with
FA treatment or control conditions were analyzed in triplicate, and data were analyzed
using Data Assist software (Thermo Fisher Scientific, v3.01, Waltham, MA).
2.12 Characterization of Enzyme Activity
HepaRG cells grown on twenty-four-well plates of were used for activity
measurements. After 72 h in culture, treatment media was removed, and the cells were
washed twice with 1xPBS; after that, 230 μL of medium was added to each well. The
medium consisted of Williams' medium E containing different concentrations of CYP 3A4
substrate, midazolam (0.1, 0.5, 1, 3, 10, 30 μM) (TRC, Catalog# KIT0040, North York, ON,
Canada) or CYP2E1 substrate, chlorzoxazone (500, 750, 1000 μM) (TRC, Catalog#
C428700, North York, ON, Canada), and incubated for 1h or 8h respectively.
compounds were dissolved in DMSO and then added to the media.

The

The final

concentration of DMSO was maintained at 0.1%, and samples were analyzed in triplicates.
The reaction was quenched by equal volume of the internal standard containing ice-cold
acetonitrile and 0.1% formic acid. The samples were analyzed for the CYP3A4 metabolite
1-hydroxymidazolam or CYP2E1 metabolite 6-hydroxychlorzoxazone (TRC, Catalog#
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H825120 North York, ON, Canada). [2H4] hydroxymidazolam (Catalog# H948423) and
[2H2] hydroxychlorzoxazone (TRC, Catalog# H825123 North York, ON, Canada) were
used as internal standards respectively.
The mass spectrometry parameters were optimized for each analyte (Dostalek et
al., 2010). The multiple reaction monitoring transitions chosen were m/z 342 → 203 for
1-hydroxymidazolam and m/z 346 → 203 for d4-hydroxymidazolam. The assay was linear
from 1 to 25 ng/mL (R2 > 0.99). The transition chosen for hydroxychlorzoxazone was m/z
183.8 → 119.8 and for d2 hydroxychlorzoxaxone was m/z 187.6 → 121.9. This assay also
showed linearity 9 to 925 ng/mL (R2 > 0.95) and precision.
2.13 Data and statistical analyses
RNA-Seq data were analyzed using IPA (Ingenuity Pathway Analysis) software for
studying the disease and other canonical pathways, utilizing the generalized pathways
that represent common properties of a signaling module using the KEGG database
(Qiagen, Foster City, CA). Differential gene expression of FA treated cells was normalized
to the control and reported as log2 of the fold change (log2FC). HemI (Heatmap Illustrator,
version 1.0) was used to generate the heatmap of differentially expressed genes. In most
cases, data were averaged for each experiment performed as triplicates and data were
presented as mean ± SEM relative to BSA for each condition. Unpaired Student's t-test
analyzed column statistics between control and FA treated groups. Data were analyzed,
and graphs were presented using Prism software (GraphPad).
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3

Results

3.1 Development of the steatosis model with HepaRG cell line
Upon treatment, the neutral lipid accumulation was visualized at 24h, 48h and 72h
utilizing ORO stain (Fig 3.2-I). There was an increasing trend in the lipid accumulation,
with 72 h post-treatment showing (Fig 3.2-II) the highest accumulation of lipids. To further
define the treatment concentration, varying range of FA (0.1 - 2.0 mM) at 72 h, were
assessed for changes in the cell viability. As shown in Fig 3.2-III, 0.5 mM of FA treatment,
did not induce any detectable toxicity to the cells and hence was used for further
characterization.

3.2 Validation of FA treated HepaRG cells as a model for steatosis
Increased total TG and cholesterol levels were observed under FA treatment
conditions. There was a 6-fold increase in triglyceride levels in FA treatment vs. control
(Fig. 3.3A). Cholesterol concentration showed ~1.3-fold increase in the FA treatment
group compared to control (Fig. 3.3B).

To assess the effect of FA treatment on

hepatocellular oxidative stress, the mean level of malondialdehyde (MDA) was measured
(Fig. 3.3C). However, there was no significant difference between the FA treatment and
control cells. This observation suggests that FA treatment may not induce oxidative
stress.
Insulin signaling, which is often hindered in steatosis, was assessed in FA treated
HepaRG cells. Total Akt levels remained constant for all treatment conditions. At every
concentration increment of insulin, a significant reduction in the levels of phospho-Akt was
noted within the FA treatment group as compared with control (Fig. 3.3D). This finding
shows reduced insulin signaling in FA treated HepaRG cells.
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In addition, we compared the transcriptomics data with a clinical study (Starmann
et al., 2012) that reported the hepatic gene expression difference between liver steatosis
(n=30) and control (n=18). Of the top 100 differentially expressed genes, 24 genes
overlapped with our dataset and are summarized in Table 3.1. The genes ACSL4/5, CAT,
PNPLA3, ATF3, GSTM5, and NR0B2, were previously reported (Stepanova et al., 2010;
Younossi et al., 2005) to show a positive correlation with NAFLD.

3.3 Pathway analysis of differentially regulated genes upon FA treatment vs. control

IPA was used to identify significant pathways affected by differential regulation of
genes from FA treatment of HepaRG cells. To further examine the model, we used the
differentially expressed (DE) genes to predict the disease state. Two hundred seventynine canonical pathways were significantly altered in the dataset of 393 DE genes (Fig.
3.4A). The top twenty pathways are listed in Table 3.2. It is important to interpret this
information with caution as the dysregulated canonical pathways were mostly represented
by a small fraction of differentially regulated genes (less than 20), in such cases the
pathway was not considered significantly dysregulated. Amongst the enriched pathways,
the pathways that were dysregulated upon FA treatment, include FXR/RXR, LXR/RXR
activation, LPS/IL-1 mediated inhibition of RXR, xenobiotic metabolism, coagulation
system and acute phase response signaling (Fig. 3.4C). Differentially expressed genes
were also grouped to predict the disease state with the IPA software (Table 3.3). It is
interesting to note the top-scoring and statistically significant (p<0.05) predictions in the
category of metabolic diseases was that of hepatic steatosis, microvesicular steatosis,
non-alcoholic fatty liver disease and steatohepatitis (Fig. 3.4B).

3.4 Protein expression pattern in FA treatment vs. control
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Similar to the gene expression pattern that predicted hepatosteatosis (Fig. 3.4C),
significant changes in protein expression that was associated with hepatocellular injury
was observed with fatty acid accumulation. Addition of fatty acids induced the proteins
PGK1, ALDOA, PGAM1 involved in glycolytic pathways as seen in steatosis, that leads to
the formation of glycerol which is the key component in TG formation (Fig. 3.5A). In
addition, we noticed a decrease in albumin production and increase in ALT production as
seen in hepatocellular injury (Fig. 3.5B). Moreover, increased protein expression of
collagen (COL18A1) and TNF-α are indicators of early stage progression to NASH.

3.5 Effect of FA treatment on immune response as well as lipid catabolism, lipid synthesis
and transport
FA treatment significantly upregulated the transcription of genes involved in
inflammation (Moylan et al., 2014), FA metabolism as well as some DMET mRNA which
are represented in Fig. 3.5B. Genes are known to be involved in inflammation and immune
response, including, PDK4 (1.54), CD36 (1.38), CD74 (1.02), TNFAIP6 (2.04), PTGFR
(0.73) and IL6 (1.28) were upregulated. This data was positively correlated with the
induction of protein expression PDK4 (2.44), CD36 (2.11) and TNFAIP6 (1.08) (data not
shown). Additionally, mRNA and protein associated with FA oxidation such as ACSL1,
ACSL4, ACOT, ACOX4 were observed to be upregulated. In addition, we also observed
increased expression mRNA and protein associated with denovo-lipogenesis ACACB,
PLIN2, PLIN4 and SCD. In addition, we noticed increased protein expression of CD36
and FABP4 contributing to the increased influx of FA in the hepatocyte-like cells.
Collectively, these results support the idea that FA accumulation in HepaRG cells exhibits
broad regulatory roles on immune response, lipogenesis, lipid catabolism and transport.

3.6 Effect of FA treatment on DMEs and nuclear receptor expression
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We compared the transcriptomes between FA treatment and control HepaRG cells
and identified significant changes in genes, suggesting the role of FA accumulation as an
initial trigger to the onset of hepatosteatosis (Fig. 3.4C). Furthermore, FA treatment
resulted in differential mRNA expression of the phase I (17 different CYP isoforms, 4
different ADH isoforms and FMO5), phase II (2 different GST isoforms, 7 different UGT
isoforms, 2 isoforms of SULT), transporter (5 different ABC superfamily, 3 of SLC
superfamily) (Fig. 3.7A).

Treatment with FA for 72h shows a statistically significant

(p<0.05) downregulation of some CYP isoforms, namely, CYP3A4, 1A2, 2B6, 2C8, 2C9
and 2C19 with log fold change in the order of -1.87, -3.25, -2.02, -1.48, -2.00 and -1.32
respectively (Table 3.2). Along with this UGT1A9 (-1.39), UGT1A6 (-0.36), SLCO2B1 (1.49). In terms of the observed protein expression (Fig. 3.7) we noticed a lower trend in
CYP2A6, CYP2C8, CYP2C9 and CYP3A5 as well as UGT2A3 and UGT2B7, however,
the results were not statistically significant.
Moreover, the expression pattern of nuclear receptors ad transcriptional factors
was further investigated. mRNA expression of NR1I2 (-1.18), NR1I3 (-1.96), PPARα (0.24) and HNF4α (-0.55) were significantly downregulated (Figure 3.7B). In agreement
with the RNA-Seq data, qRT-PCR results indicated that expression of the nuclear
receptors PXR (NR1I2) and CAR (NR1I3) and CYP3A4 was markedly reduced upon FA
treatment (Fig. 3.7C). Furthermore, mRNA and protein of transcriptional regulator,
AKR1B10 was positively increased. This suggests that FA accumulation in steatosis
induce AKR1B10 that may modulate the lipid metabolism as well as basal expression of
drug-metabolizing enzymes (DMEs) in hepatocytes.

3.7 Functional activity of CYP3A4 in control and fatty acid treatment
CYP3A4, the most abundant human hepatic CYP (Saravanakumar et al., 2019) ,
along with PXR and CAR expression was assessed using qRT-PCR. CYP3A4 enzyme
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activity in FA-treated HepaRG was assessed using midazolam as a substrate. Upon FA
treatment, the CYP3A4 enzyme activity was significantly reduced. FA-treatment resulted
in a 10-fold reduction in CYP3A4 (maximal rate of metabolism, Vmax) activity compared
to the control at 10 µM (Fig. 3.8B). Both our RNA-seq, PCR data as well as enzyme activity
showed marked downregulation in CYPs and its corresponding nuclear receptors,
demonstrating the link between lipid metabolism in steatosis cells with that of xenobiotic
metabolism in liver cells.
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4

Discussion
We have established an in-vitro model for hepatic steatosis and validated this

model by various approaches.

Utilizing transcriptomic analyses, we have examined

altered molecular signaling pathways upon FA accumulation in HepaRG cells. In addition,
we collaborated this with proteomics analysis. Our data agree with earlier reports
describing the response to FA loading on lipogenesis as well as inflammatory modulators
(Rubin et al., 2015; Parafati et al., 2018).
Hepatic steatosis is characterized by increased accumulation of neutral lipids and
TG in intracytoplasmic micro/macrovesicles triggered by multiple factors especially in the
presence of FA (Gómez-Lechón, Jover and Donato, 2009). Presence of lipid droplets and
increased TG accumulation has been previously reported for in vitro cultures in the
presence of long-term stimuli with (unsaturated) oleic acid (Antherieu et al., 2011; Rogue
et al., 2014) and short-term treatment with a mixture of oleate and palmitate (O/P) (Dave,
Tilles and Vemula, 2018; Chavez-Tapia, Rosso and Tiribelli, 2012; Brown et al., 2013).
The investigations on hepatic lipid content in NAFLD and NASH patients reveals increased
levels of O/P and a trend that shows a shift towards O/P with the disease progression
(Araya et al., 2004). Hence, it was physiologically relevant to treat the HepaRG cells with
O/P to stimulate steatosis. Moreover, we used a 2:1 ratio of O/P to mitigate the lipotoxic
effects of palmitate treatment (Montell et al., 2001; Wei, Wang and Pagliassotti, 2007).
Here we report a 6-fold increase in TG content as well as increased lipid-filled vesicles in
HepaRG cells after a 72h stimulus with 0.5mM of O/P (2:1). This in vitro model also
showed a positive correlation with several genes associated with de-novo lipogenesis
(Table 3.3) and inflammation. Thereby, providing a molecular signature resembling liver
steatosis.
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HepaRG cells treated with 0.5 mM O/P (2:1) showed a significant downregulation
of PXR, CAR, and PPARα as well as the target CYP mRNA. Our results is in agreement
with previous reports showing downregulation of PPARα in hepatic steatosis (Pawlak,
Lefebvre and Staels, 2015). However, in contrast to our observations, Tanner et al.
reported no change in mRNA of DMETs as well as the nuclear receptors such as PXR,
CAR, and PPARα upon treatment with O/P (Tanner et al., 2018). However, the FA
treatment method was different from our experiment including the proportion of the two
FA (1:1 O/P vs. 2:1 O/P), incubation period (24h vs. 72h) and concentration of FA
treatment (125 µM vs. 500 µM), which might explain the discrepancies between the two
studies.
Previous studies have reported the impact of hepatic steatosis on P450 enzymes
and cell membrane transporters (Lake et al., 2011; Fisher et al., 2009; Hardwick et al.,
2013). In our NAFLD model, the gene expression of CYP including CYP3A4, 1A2, 2B6,
2C8, 2C9, 2C19 and 4A11 were significantly reduced. Additionally, we also observed a
lower trend in CYP2A6, CYP2C8, CYP2C9 and CYP3A5 protein expression, however this
was not statistically significant findings. Similar changes in gene expression were
previously observed by Donato et al. (Donato et al., 2006) using plated human
hepatocytes, but these were only exposed to FFA for 14 h and the impact on other ADME
proteins were not extensively explored. Kostrzewski et al. (Kostrzewski et al., 2017),
reported using a 3D human hepatocytes model of NAFLD that the metabolic rates of
CYP3A4 and CYP2C9 to be reduced, with no changes in the genomic expression. These
contrasted with our findings that show significant mRNA change, as our model is specific
to early stages of steatosis that reverts during disease progression. In summary, utilizing
an in vitro model of liver steatosis, our data demonstrate broad alterations in ADME, upon
FA loading of HepaRG cells.
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Increased infiltration of the FA in the liver results in an alteration in β-oxidation via
TCA cycle and increased TG synthesis to compensate with the overload, that eventually
leads to hepatocyte enlargement (Diraison, Moulin and Beylot, 2003). This transition is
reflected in HepaRG FA treatment with the upregulation of aldo–keto reductase (AKR)
1B10 which regulates acetyl-CoA carboxylase (ACC)-catalyzed reaction step of de novo
lipogenesis (Bitter et al., 2015). Upregulation of PLIN2 is also noted, which coats lipid
droplets and prevents TG to undergo lipolysis via LPL. Downregulation of PPARα which
is important in lipid metabolism and regulates the expression of PLIN2 is noteworthy and
consistent with the literature (McManaman et al., 2013).
High-sensitivity C-reactive protein is a clinical predictor of NAFLD (FierbinteanuBraticevici et al., 2011); in the current study, this marker was upregulated along with a
minimal increase in serum amyloid A2 and IL-6 (Table 3.4). However, induction of acutephase proteins upon FA treatment shows the early signs of progression from steatosis to
the development of NASH. Despite the induction of a few inflammatory markers, there is
no evidence to show the presence of oxidative stress in the cells, and hence this model is
more representative of hepatic steatosis and co-culture with immune cells is warranted to
optimize a model for NASH.
The nuclear receptor, Hepatocyte Nuclear Factor 4-alpha (HNF4α), regulated by
the presence of FA is reported to modulate both xenobiotic and FA metabolism (Merrell
and Cherrington, 2011). It is to be noted that, CYP2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and
3A4/5 are controlled by upstream regulator HNF4α via PXR and CAR. Their xeno-sensing
mechanism also plays a central role in lipid homeostasis and hepatocyte differentiation
(Jover, Moya and Gómez-Lechón, 2009). HNF4a deficient mice are shown to have
increased lipid accumulation in the liver and reduced serum cholesterol and TG levels
(Hayhurst et al., 2001). Using our transcriptomics data, we observed a downregulation of
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HNF4a which may contribute to the progression to steatosis as well as dysregulation in
DMET. However, most of the nuclear receptors and transcriptional regulator could not be
identified in the proteomics assay due to the low abundance in cells.
Comparative analysis of transcriptomics and proteomics reveal important pattern
of many proteins as seen in AKR1B10. However, there is a mismatch in DME mRNA and
protein expression, this could be partly explained due to changes in posttranslational
modifications and cellular location of proteins (Schwanhäusser et al., 2011). Recently, Liu
et al. reviewed the relationship between mRNA and proteins under different scenarios
(Liu, Beyer and Aebersold, 2016). They concluded that the correlations may depend on
many factors including applied techniques used in quantification of mRNA and protein,
cell state, and posttranscriptional and posttranslational processes. These might have
caused the observed variability. This may cause the change in expression pattern of the
endpoints, primarily due to the time of harvest from the vitro culture. Also, the samples for
the protein expression study in HepaRG cells were harvested from P17-P20 in comparison
to P16 for mRNA samples. We believe the different passages are causing variability and
leading to loss of significance in the assessment of CYP450 proteins that are generally
present in low abundance in HepaRG cells.
In conclusion, our study presents an in-vitro model of steatosis demonstrating that
lipid-loaded HepaRG cells are a suitable model for studying the effect of NAFLD on drugmetabolizing enzymes and transporters. Utilizing transcriptomics and proteomics data,
we established the experimental model (2:1 O/P in HepaRG) showed a molecular
signature that closely resembled hepatic steatosis leading to steatohepatitis. Additionally,
we reported a significant downregulation of various DMET genes, along with a proposed
mechanism for the possible initial ‘hits’ that leads to steatosis. FA-loaded HepaRG cells
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can be a valuable in-vitro tool to model the disposition of new chemical entities in the
disease state and may further aid in the appropriate design of new drugs for NAFLD.
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5. Figures and Tables
Graphical Abstract

Figure 3.1. Model development of cellular steatosis by Oil Red O staining and cell
viability assay.
(Fig 3.1-I) HepaRG cells were treated for 24h, 48h, 72h with control (A, C, E) vs. 0.5 µM
of O/P 1:2 treatment (B, D, F). Images were taken under a light microscope at 20X
magnification. The scale bars denote 85 µm. (Fig 1-II) For quantitative analysis of fat
incorporation, Oil Red O stain was extracted and measured, OD @ 492 nm, following O/P
treatment for 24, 48 and 72h respectively. Mean + SD (assayed in triplicate) are
represented as relative to control cells. (Fig 1-III) Cells were incubated in the presence of
increasing concentrations from 0.1 - 2.0 mM of O/P (1:2) mixture for 72h. Data from the
WST-1 tests are depicted as means + SD (three biological replicates) and given relative
to control cells (NC). PC (positive control) cells were treated with 0.1 mM of clotrimazole.
A non-toxic and steatosis-inducing concentration of 0.5 mM O/P at 72h incubation was
selected for further analyses
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Figure 3.2: Model development of cellular steatosis by Oil Red O staining and cell
viability assay.
(Fig 1-I) HepaRG cells were treated for 24h, 48h, 72h with control (A, C, E) vs. 0.5 µM of
O/P 1:2 treatment (B, D, F). Images were taken under a light microscope at 20X
magnification. The scale bars denote 85 µm. (Fig 1-II) For quantitative analysis of fat
incorporation, Oil Red O stain was extracted and measured, OD @ 492 nm, following O/P
treatment for 24, 48 and 72h respectively. Mean + SD (assayed in triplicate) are
represented as relative to control cells. (Fig 1-III) Cells were incubated in the presence of
increasing concentrations from 0.1 - 2.0 mM of O/P (1:2) mixture for 72h. Data from the
WST-1 tests are depicted as means + SD (three biological replicates) and given relative
to control cells (NC). PC (positive control) cells were treated with 0.1 mM of clotrimazole.
A non-toxic and steatosis-inducing concentration of 0.5 mM O/P at 72h incubation was
selected for further analyses (***p<0.001).
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Figure 3.3: Model validation of cellular steatosis.
Differentiated HepaRG cells were treated with BSA alone (control) or with 0.5 µM
palmitate: oleate (1: 2) (FA treatment) for 72 h prior to assaying triglyceride (A) and
cholesterol (B) content. (C) The mean level of reactive oxygen species (ROS) detected
via measuring malondialdehyde (MDA) as an indicator of oxidative stress is shown. (D)
Cells were treated for 12h in serum free media (Starvation). Cells were then stimulated
with insulin (1, 10, 100 nM) for 10 min before harvest. Phosphorylated Akt (Ser473) and
total Akt were assayed in ELISA kit. Error bars represent standard deviation. All samples
were assayed in triplicates. Asterisks indicate a significant (*P < 0.05; **P <0.01; ***P
<0.001) difference compared to control.
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Figure 3.4: Differential expressed genes and proteins in HepaRG cells with FA treatment.
(A) Venn diagram indicating the differentially up- and down-regulated genes quantified using proteomics and transcriptomics studies;
based on log FC > 0.58; pvalue < 0.05. (B) Venn diagram showing the differentially up- and down-regulated proteomics quantified
using SWATH-MS. (C) Listed are the significant gene expression change that predict the model disease state to closely resemble
steatosis, microvesicular hepatic steatosis, steatohepatitis as well as non-alcoholic fatty liver upon fatty acids addition to HepaRG cells.
Red and green denote downregulated and upregulated genes, respectively. (D) The top 10 dysregulated pathway predicted by IPA.
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Figure 3.5: Changes in protein expression involved in glycolysis and in the
progression of NAFL.
(A) The protein expression quantified by SWATH-MS of glycolytic proteins in control and
FA treated HepaRG cells are shown. (B, C) The proteins involved in hepatocellular injury
as well as markers for the progression of NAFL are shown. The expression of proteins is
expressed as pmol/mg of protein. The figure is the mean of protein expression among the
replicates; * denotes p<0.05.
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Figure 3.6: Transcripts and proteins involved in lipid catabolism, lipid synthesis and
lipid transport.
The figure denotes the log fold change (FC) of expression in FA treatment vs. control. The
mRNA and protein response are denoted as shown. The figure is shown as mean of log
(FC) with SEM among the replicates.
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Figure 3.7: Fold change (logFC) of drug metabolizing genes and proteins upon
treatment.
Differentiated HepaRG cells were treated with BSA alone (control) or 0.5 µM
palmitate:oleate (1: 2) (FA treatment) for 72 h prior to SWATH-MS based proteomics
analysis. (A) Heat map illustrating cytochrome P450 (CYP), Other Phase 1, Phase 2 and
transporters mRNA and proteins are shown. Log FC of mRNA and protein expression as
shown in the figure (B) Heat map of nuclear receptors and transcriptional regulators are
expressed as log FC of mRNA and proteins. (C) mRNA expression of control and fatty
acid treated HepaRG cells from q-PCR are expressed. All samples were assayed in
triplicates and samples are represented as an average of log2FC. X denotes absence of
expression due to presence of proteins below the limit of quantification; * denotes p<0.05.
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Figure 3.8: CYP3A4 functional activity in control and fatty acid treatment.
CYP3A4 enzyme activity assessed at different substrate concentration (30, 10, 3, 1, 0.5
µM) show significant downregulation upon FA treatment. The significance was calculated
with P <0.05.
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Table 3.1: Comparison of transcriptional expression profile of lipid loaded HepaRG model and biobank liver samples

Gene Name

Description

RNA-seq/ FC

P value

q-PCR/
FC
(Steatosis/cntrl)

P value

(From current study)

(Starmann et al., 2012)
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SUSD2

sushi domain containing 2

6.53E-01

2.50E-16

1.47E+00

6.90E-02

ACSL4

acyl-CoA synthetase long-chain family
member 4
1.51E+00

4.66E-11

2.11E+00

2.90E-02

ATF3

crystallin lambda 1

6.75E-01

2.18E-09

1.57E+00

1.74E-01

INMT

indolethylamine N-methyltransferase

3.24E-01

3.75E-09

1.03E+00

9.19E-01

MAT1A

methionine adenosyltransferase 1A

6.96E-01

6.23E-09

8.55E-01

3.21E-01

LUM

lumican

1.33E+00

1.83E-07

1.45E+00

6.10E-02

ACSL5

acyl-CoA synthetase long-chain family
member 5
1.25E+00

4.28E-06

1.38E+00

4.90E-02

PNPLA3

patatin like phospholipase domain
containing 3
7.62E-01

4.20E-05

2.15E+00

2.00E-03

SH3KBP1

SH3 domain containing kinase binding
protein 1
1.31E+00

2.18E-04

1.38E+00

1.43E-01

ID3

inhibitor of DNA binding 3, HLH protein 7.10E-01

2.66E-04

1.01E+00

9.68E-01

SQSTM1

sequestosome 1

1.17E+00

2.30E-03

1.32E+00

1.30E-01

AKR1B10

aldo-keto reductase family 1 member
B10
1.15E+00

6.89E-03

2.73E+00

7.00E-02
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DGAT2

diacylglycerol O-acyltransferase 2

8.72E-01

1.49E-02

1.31E+00

2.31E-01

CYP3A43

cytochrome P450 family 3 subfamily A
member 43
3.26E-01

3.41E-02

7.77E-01

4.05E-01

ITGA3

integrin subunit alpha 3

1.09E+00

1.01E-01

1.45E+00

1.33E-01

STMN1

stathmin 1

1.07E+00

2.22E-01

NA

NA

GSTM1

glutathione S-transferase mu 1

8.53E-01

2.27E-01

NA

NA

KRT18

keratin 18

1.05E+00

3.46E-01

1.18E+00

3.06E-01

CAT

catalase

9.58E-01

3.64E-01

7.22E-01

5.21E-01

NR0B2

nuclear receptor subfamily 0 group B
member 2
6.44E-01

3.78E-01

2.27E+00

1.00E-03

DEFB1

defensin beta 1

9.46E-01

5.26E-01

2.36E+00

1.00E-03

LRRFIP2

LRR binding FLII interacting protein 2

1.01E+00

8.97E-01

1.80E+00

5.00E-03

KRT8

keratin 8

1.01E+00

9.07E-01

1.65E+00

4.10E-02

MAGED2

MAGE family member D2

1.00E+00

9.98E-01

1.46E+00

1.00E-02

Table 3. 2: Top 20 differentially regulated canonical pathway upon FA treatment
Ingenuity
Pathways

Canonical -log(pvalue)

Ratio

FXR/RXR Activation

24.2

0.278

LXR/RXR Activation

21.4

0.264

15.8

0.309

Mediated
of RXR 15.7

0.158

Superpathway
Melatonin
Degradation
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LPS/IL-1
Inhibition
Function

of

Nicotine Degradation

15.3

0.317

Estrogen
Biosynthesis

13.1

0.385

PXR/RXR Activation

12.7

0.277

Serotonin
Degradation

12.6

0.253

Molecules
APOA4, TF, SLC10A1, SLC22A7, G6PC, RBP4, NR5A2, APOC1, APOC3,
APOM, KNG1, BAAT, AMBP, APOL1, ALB, UGT2B4, LIPC, PKLR, ABCG5, FGA,
ABCG8, CYP8B1, VTN, SAA2, MLXIPL, APOA2, FETUB, LCAT, APOE,
SULT2A1, AHSG, HPR, CYP7A1, TTR, NR1I2
IL1RL1, APOA4, TF, LBP, RBP4, IL6, APOC1, APOC3, APOM, KNG1, AMBP,
APOL1, ALB, MYLIP, CCL7, TNFRSF1B, ABCG5, FGA, ABCG8, CD36, VTN,
TLR3, SAA2, CCL2, MLXIPL, APOA2, LCAT, APOE, AHSG, HPR, CYP7A1, TTR
UGT2B4, CYP3A7, CYP4X1, UGT2B10, UGT1A7 (includes others), UGT2B7,
CYP1A1, SULT1A2, CYP3A4, SULT1E1, UGT1A1, CYP2C9, CYP4B1, CYP2B6,
CYP1A2, UGT2B15, UGT2A3, CYP2C8, CYP3A5, SULT2A1, CYP2A6 (includes
others)
IL1RL1, CYP3A7, CYP4A11, SLC10A1, SULT1A2, GSTA2, CYP3A4, LBP,
NR5A2, APOC1, CYP2C9, FMO5, ACSL1, CYP2B6, GSTA1, CYP2A6 (includes
others), GSTT2/GSTT2B, ALDH1L1, FABP4, LIPC, TNFRSF1B, ABCG5,
ALDH6A1, SULT1E1, ABCG8, CHST11, ACSL4, CYP2C8, ACSL3, CYP3A5,
APOE, SULT2A1, CYP7A1, CHST15, NR1I2
UGT2B4, CYP3A7, CYP4X1, UGT2B10, UGT1A7 (includes others), UGT2B7,
CYP1A1, CYP3A4, UGT1A1, CYP2C9, FMO5, CYP4B1, CYP2B6, CYP1A2,
UGT2B15, UGT2A3, CYP2C8, CYP3A5, INMT, CYP2A6 (includes others)
HSD17B3, HSD17B2, CYP3A7, CYP4X1, CYP1A1, CYP3A4, CYP2C9, AKR1C4,
CYP4B1, CYP2B6, CYP1A2, CYP2C8, CYP3A5, HSD17B13, CYP2A6 (includes
others)
CYP3A7, UGT1A7 (includes others), G6PC, GSTA2, CYP3A4, IL6, UGT1A1,
CYP2C9, IGFBP1, CYP2B6, CYP1A2, CYP2C8, CYP3A5, SULT2A1, GSTA1,
CYP2A6 (includes others), CYP7A1, NR1I2
UGT2B4, DHRS9, ALDH1L1, ADH1C, UGT2B10, UGT1A7 (includes others),
UGT2B7, SULT1A2, ADH1A, ADH4, SULT1E1, UGT1A1, ADHFE1, ADH1B,
UGT2B15, UGT2A3, PECR, ADH6, SULT2A1
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Bupropion
Degradation

10.5

0.44

Acetone Degradation

10.1

0.407

Atherosclerosis
Signaling

10

0.165

Xenobiotic
Metabolism Signaling

8.92

0.105

8.65

0.314

8.4

0.129

8.33

0.5

F12, F7, FGB, FGA, F10, SERPINC1, FGG, F13B

7.84

0.268

UGT2B4, UGT2B10, UGT1A7 (includes others), UGT2B7, UGT2B15, UGT2A3,
SULT1A2, DIO1, SULT1E1, SULT2A1, UGT1A1

7.72

0.262

F12, KNG1, FGB, FGA, F10, COL5A3, COL1A1, SERPINC1, COL18A1, FGG,
F13B

7.64

0.538

AKR1D1, BAAT, CYP3A4, SCP2, AKR1C4, CYP8B1, CYP7A1

Coagulation System
Acute
Phase
Response Signaling
Extrinsic Prothrombin
Activation Pathway
Thyroid
Hormone
Metabolism II (via
Conjugation
and/or
Degradation)
Intrinsic Prothrombin
Activation Pathway
Bile
Acid
Biosynthesis, Neutral
Pathway

Ethanol Degradation II 7.21

0.27

Hepatic Fibrosis /
Hepatic Stellate Cell 6.47
Activation

0.109

CYP4B1, CYP2B6, CYP1A2, CYP3A7, CYP4X1, CYP2C8, CYP1A1, CYP3A5,
CYP3A4, CYP2C9, CYP2A6 (includes others)
CYP4B1, CYP2B6, CYP1A2, CYP3A7, CYP4X1, CYP2C8, CYP1A1, CYP3A5,
CYP3A4, CYP2C9, CYP2A6 (includes others)
APOA4, COL5A3, COL1A1, PLA2G6, RBP4, IL6, APOC1, APOC3, COL18A1,
APOM, CXCL8, CD36, CCL2, APOA2, RARRES3, LCAT, PLA2G12B, APOE,
ICAM1, APOL1, ALB
UGT2B11, CYP3A7, UGT1A7 (includes others), CYP1A1, SULT1A2, GSTA2,
CYP3A4, IL6, CYP2C9, FMO5, CYP2B6, GSTA1, FGFR3, UGT2B4,
GSTT2/GSTT2B, ALDH1L1, UGT2B10, UGT2B7, ALDH6A1, MAP3K12,
SULT1E1, UGT1A1, CHST11, CYP1A2, UGT2B15, CYP2C8, CYP3A5,
SULT2A1, CHST15, NR1I2
F12, F7, KNG1, FGB, FGA, F10, SERPINC1, PLG, SERPIND1, FGG, F13B
TF, TNFRSF1B, SOCS3, FGA, LBP, RBP4, IL6, CRP, PLG, FGG, SOD2, HRG,
SAA2, FGB, APOA2, SOCS1, AHSG, AMBP, RBP5, SERPIND1, ALB, TTR

DHRS9, ACSL1, ALDH1L1, ADH1C, ADH1B, ADH1A, PECR, ADH4, ADH6,
ADHFE1
IL1RL1, COL7A1, BAMBI, KDR, TNFRSF1B, COL6A1, COL27A1, CTGF,
COL5A3, IGFBP5, COL4A4, LBP, COL1A1, IL6, COL18A1, CXCL8, CCL2, MYL5,
CXCL3, ICAM1

Table 3.3: Classification of differentially expressed genes upon FA treatment vs. control predictive of physiological disease
state
Ensembl

Classification
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Symbol

Entrez Gene Name

ENSG00000151726

ACSL1

acyl-CoA synthetase 0.775
long
chain
family
member 1

2.73E-08

Cytoplasm

enzyme

ENSG00000068366

ACSL4

acyl-CoA synthetase 0.602
long
chain
family
member 4

6.25E-05

Cytoplasm

enzyme

ENSG00000130203

APOE

apolipoprotein E

9.44E-06

Extracellul
ar Space

transporter

CCL2

C-C motif chemokine 1.48
ligand 2

1.08E-06

Extracellul
ar Space

cytokine

CD36

CD36 molecule

6.01E-05

Plasma
Membrane

transmembra
ne receptor

ENSG00000187048

CYP4A11

cytochrome
P450 -1.28
family 4 subfamily A
member 11

2.48E-06

Cytoplasm

enzyme

ENSG00000185000

DGAT1

diacylglycerol
acyltransferase 1

4.67E-05

Cytoplasm

enzyme

ENSG00000170323

FABP4

fatty
acid
protein 4

2.98E-07

Cytoplasm

transporter

ENSG00000108691
ENSG00000135218

Hepatic
Steatosis

Expr Log Expr p- Location
Ratio
value

-0.723

1.38

O- -0.711

binding 1.86

Family
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ENSG00000131482

G6PC

glucose-6-1.22
phosphatase catalytic
subunit

4.68E-07

Cytoplasm

phosphatase

ENSG00000171766

GATM

glycine
amidinotransferase

4.84E-08

Cytoplasm

enzyme

ENSG00000124713

GNMT

glycine
methyltransferase

0.00999

Cytoplasm

enzyme

ENSG00000170509

HSD17B1
3

hydroxysteroid
17- -1.54
beta dehydrogenase
13

2.35E-04

Extracellul
ar Space

enzyme

ENSG00000146678

IGFBP1

insulin
like
growth 1.04
factor binding protein 1

2.47E-05

Extracellul
ar Space

other

ENSG00000136244

IL6

interleukin 6

1.28

0.00293

Extracellular cytokine
Space

ENSG00000127528

KLF2

Kruppel like factor 2

-0.98

0.0315

Nucleus

transcription
regulator

ENSG00000129988

LBP

lipopolysaccharide
binding protein

0.815

4.84E-08

Plasma
Membrane

transporter

ENSG00000166035

LIPC

lipase C, hepatic type

-0.817

0.0059

Extracellul
ar Space

enzyme

ENSG00000148343

MIGA2

mitoguardin 2

-0.716

0.00254

Plasma
Membrane

other

-0.962

N- -1.39

ENSG00000106384

MOGAT3

monoacylglycerol
acyltransferase 3

O- -1.01

0.0303

Cytoplasm

enzyme

NEIL1

Nei
like
glycosylase 1

DNA -0.731

0.024

Nucleus

enzyme

ENSG00000147872

PLIN2

perilipin 2

1.39

4.21E-10

Plasma
Membrane

other

ENSG00000130988

RGN

regucalcin

-1.01

3.12E-04

Nucleus

enzyme

solute carrier family 2
-0.731
member 4

0.0184

Plasma
Membrane

transporter

SOD2

superoxide dismutase
0.896
2

7.55E-09

Cytoplasm

enzyme

TLR2

toll like receptor 2

0.628

0.00766

Plasma
Membrane

transmembra
ne receptor

ENSG00000213996

TM6SF2

transmembrane
6 -1.41
superfamily members
2

0.00787

Plasma
Membrane

other

ENSG00000265972

TXNIP

thioredoxin interacting 0.78
protein

1.04E-06

Cytoplasm

other

ENSG00000140398

ENSG00000181856

Microvesicular
hepatic
steatosis

Nonalcoholic
fatty
liver
disease
SLC2A4
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ENSG00000112096
ENSG00000137462

Steatohepatitis

Table 3.4: Classification of differentially expressed drug metabolizing genes and proteins upon FA treatment vs. control
Category

Feature

Description

Gene Name

ENSG00000187758

alcohol dehydrogenase 1A (class I);
alpha polypeptide
alcohol dehydrogenase 1B (class I);
beta polypeptide
alcohol dehydrogenase 1C (class I);
gamma polypeptide
alcohol dehydrogenase 4 (class II); pi
polypeptide
cytochrome P450 family 1 subfamily A
member 2
cytochrome P450 family 2 subfamily A
member 6
cytochrome P450 family 2 subfamily B
member 6
cytochrome P450 family 2 subfamily
C member 8
cytochrome P450 family 2 subfamily
C member 9
cytochrome P450 family 3 subfamily A
member 4
cytochrome P450 family 3 subfamily A
member 5
cytochrome P450 family 3 subfamily A
member 7
cytochrome P450 family 4 subfamily A
member 11
cytochrome P450 family 4 subfamily F
member 2

ENSG00000196616
ENSG00000248144
ENSG00000198099
ENSG00000140505
ENSG00000255974
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ENSG00000197408
ENSG00000138115
ENSG00000138109
ENSG00000160868
ENSG00000106258
ENSG00000160870
ENSG00000187048
ENSG00000186115

p-value

ADH1A

logFC
(mRNA)
-1.30

ADH1B

-1.45

5.93E-09

ADH1C

-1.96

1.41E-08

ADH4

-1.70

6.97E-09

CYP1A2

-3.25

1.25E-06

CYP2A6

-2.61

2.49E-06

CYP2B6

-2.02

1.60E-04

CYP2C8

-1.48

1.62E-08

CYP2C9

-2.00

2.17E-10

CYP3A4

-1.87

1.60E-04

CYP3A5

-0.80

4.29E-06

CYP3A7

-1.29

2.98E-03

CYP4A11

-1.28

2.48E-06

CYP4F2

-1.34

2.73E-08

1.01E-06

ENSG00000167910

cytochrome P450 family 7 subfamily A CYP7A1
member 1
cytochrome P450 family 8 subfamily B CYP8B1
member 1
flavin containing monooxygenase 5
FMO5

-2.71

7.50E-06

-1.61

6.80E-06

-1.21

9.44E-06

ENSG00000122787

aldo-keto reductase family 1-member AKR1B10
B10

2.17

1.41E-06

ENSG00000198610

aldo-keto reductase family 1-member C4AKR1C4

-1.54

1.66E-07

ENSG00000241119

UGT1A9

-1.40

7.55E-07

UGT2B15

-0.95

9.82E-08

UGT2A3

-0.68

4.72E-06

UGT2B7

-1.09

8.72E-08

UGT2B11

-1.27

1.39E-04

ENSG00000133433
ENSG00000243955

UDP glucuronosyltransferase family
1-member A9
UDP glucuronosyltransferase family
2-member B15
UDP glucuronosyltransferase family
2-member A3
UDP glucuronosyltransferase family
2-member B7
UDP glucuronosyltransferase family
2-member B11
glutathione S-transferase theta 2B
glutathione S-transferase alpha 1

GSTT2B
GSTA1

-1.07
-0.91

8.48E-03
6.51E-08

ENSG00000105398

sulfotransferase family 2A member 1

SULT2A1

-0.75

6.91E-07

ENSG00000109193
ENSG00000121270

sulfotransferase family 1E member 1
ATP binding cassette subfamily C
member 11
ATP binding cassette subfamily G
member 8
ATP binding cassette subfamily G
member 5

SULT1E1
ABCC11

-1.41
-1.36

1.64E-04
3.13E-05

ABCG8

-0.97

6.30E-04

ABCG5

-1.66

8.38E-04

ENSG00000180432
ENSG00000131781

ENSG00000196620
ENSG00000135220
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Phase II

ENSG00000171234
ENSG00000213759

ENSG00000143921
Transporters

ENSG00000138075

ENSG00000117834
ENSG00000100652

solute carrier family 5 member 9
solute carrier family 10 member 1

SLC5A9
SLC10A1

-1.23
-1.63

1.22E-05
5.91E-10

ENSG00000137491

solute
carrier
organic
anion
transporter family member 2B1
solute
carrier
organic
anion
transporter family member 1B1
nuclear receptor subfamily 1 group D
member 1
nuclear receptor subfamily 1 group I
member 2
hepatocyte nuclear factor 4 alpha

SLCO2B1

-1.49

1.02E-06

SLCO1B1

-0.39

5.49E-02

NR1D1

-0.52

2.11E-03

NR1I2

-1.18

3.70E-06

HNF4A

-0.55

7.03E-05

ENSG00000134538
ENSG00000126368
Nuclear
Receptors
Transcription
factors

&

ENSG00000144852
ENSG00000101076
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Abbreviation
ANXA1 - Annexin A1
APOA4 - Apolipoprotein A-IV
APOE - Apolipoprotein E
APPL1 - DCC-interacting protein 13-alpha
ATP1A2 - Sodium/potassium-transporting ATPase subunit alpha-2
BCAT2 - Branched-chain-amino-acid aminotransferase
CALD1 - Caldesmon
CLTB - Clathrin light chain B
DBNL - Drebrin-like protein
EIF4H - Eukaryotic translation initiation factor 4H
EIF5B - Eukaryotic translation initiation factor 5B
G6PC - Glucose-6-phosphatase
GMPPA - Mannose-1-phosphate guanyltransferase alpha
GSTA4 - Glutathione S-transferase A4
H2AFY2 - Core histone macro-H2A.2
HMGB1 - High mobility group protein B1
KRT10 - Keratin, type I cytoskeletal 10
LTF

- Lactotransferrin

NAFLD - Nonalcoholic fatty liver disease
NASH - Nonalcoholic steatohepatitis
NBPF7 - Putative neuroblastoma breakpoint family member 7
NSUN2 - RNA cytosine C(5)-methyltransferase NSUN2
NT5C - 5'(3')-deoxyribonucleotidase, cytosolic type
PALLD - Palladin
PDCD5 - Programmed cell death protein 5
PIGR - Polymeric immunoglobulin receptor
PLIN2 - Perilipin-2
PPP1R7 - Protein phosphatase 1 regulatory subunit 7
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PRKACB - cAMP-dependent protein kinase catalytic subunit beta
PTMS - Parathymosin
RAB23 - Ras-related protein Rab-23
RBM4 - RNA-binding protein 4
RBM5 - RNA-binding protein 5
SH3BGRL3 - SH3 domain-binding glutamic acid-rich-like protein 3
SLC26A2 - Sulfate transporter
SLC35A3 - UDP-N-acetylglucosamine transporter
SNX1 - Sorting nexin-1
SNX6 - Sorting nexin-1
TSN - Translin
TSTA3 - GDP-L-fucose synthase
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Abstract
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a global epidemic,
manifested in over 10% of the world population, although often is undiagnosed. Liver
biopsies are the only gold standard available for the confirmation of the disease state.
Other non-invasive diagnostics such as ultrasound and MRI are inaccurate or expensive
for routine use. Many markers for disease state are available that detect the onset of
inflammation and fibrosis from moderate-to-high accuracy. However, there is a major
shortcoming in specific biomarkers that can distinguish NAFLD livers from normal in early
stages of the onset of disease.
Methods: SWATH-MS based Data-independent acquisition (DIA) strategy is used in the
proteomics analysis due to its ability in quantification of low-abundant proteins with high
accuracy. Hence a DIA based strategy is used to evaluate the dysregulated proteins in
two in vitro models of hepatic steatosis and to compare it with human liver tissue (n=116)
showing progressive stages of NAFLD.
Results: More than 2,500 proteins were identified in HepaRG and human hepatocyte
model as well as human liver tissue. Within the hepatocyte model, 40 proteins were
dysregulated in steatosis. These proteins were screened in liver tissue and 6 common
proteins (PLIN2, ANAX1, H2AFY2, APOE, GCFHR, SNX1) showed significant changes in
protein expression. In addition, receiver operative curve (ROC) analysis revealed all
markers were relevant in the prediction of the disease state with moderate-to-high
selectivity and specificity. Especially, PLIN2, ANAX1 and H2AFY2 showed receiver
operative area under the curve (ROAUC) ≥ 0.7.
Keywords
NAFLD, DIA, SWATH-MS, Steatosis, Biomarkers

138

1. Introduction

Nonalcoholic fatty liver disease (NAFLD) is reported to be the leading cause
of end stage liver disease and liver transplantation 1. It affects up to 30% of the
adult population, especially in western countries 2. Moreover, 10-15% of the
patients diagnosed with NASH, develop cirrhosis and hepatocellular carcinoma 3.
Despite the recent advancement in diagnostics, liver biopsy is the only gold
standard method for confirmation of NAFLD 4.
Histological testing of liver biopsies, along with multiple scoring scales and
algorithms, are employed to classify the progression of the disease 5. However,
liver biopsies are invasive, expensive and poorly accepted among the patient
population. In addition, owning to the heterogenicity of lipid localization in liver as
seen with severity of steatosis, diagnosis from liver biopsies may be biased and
lead to misclassification 6. Noninvasive imaging techniques have improved over
time and are used to help determine the progression of steatosis, inflammation,
hepatocellular ballooning, fibrosis, as well as liver stiffness

4, 7

. However,

ultrasound fail to detect steatosis with the grade of < 20%, in addition, more precise
diagnostics such as MRI, are expensive for routine testing 4. Hence, biomarkers
that best predict the severity and progression of disease state are therefore
needed for diagnosis and therapy. In addition, it can also greatly improve the
current drug development process for NAFLD. Due to the complexity involved in
the disease progression of NAFLD, it is highly unlikely that a single biomarker can
precisely delineate steatosis and NASH group. Henceforth, a list of proteins that
are dysregulated with disease progression alongside other variables (such as age,
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gender and diabetes) would present the robustness for probable biomarker
identification.
With the advent of novel proteomics technologies, multiple studies have
reported to identify various biomarkers in NAFLD. Bell et al. reported 55 as well as
15 proteins that were dysregulated in NAFLD and NASH with advanced fibrosis
along with NASH and NASH with advanced fibrosis, respectively 8, 9. However, not
much is known about the dysregulated proteins between simple steatosis and
NASH groups. Proteomics employing sequential acquisition of theoretical mass
spectra (SWATH-MS) is a powerful tool that aims to determine the relative amount
of proteins from low-throughput biological samples

10-12

. Data independent

acquisition based total protein approach (DIA-TPA) is more commonly used in
untargeted proteomics, to compare the protein levels between the groups. This
approach is sensitive to capture the low abundant proteins extracted from cells as
well tissue homogenates, and hence an ideal tool for biomarker discovery 12.
The objective of this study is to identify a list of secretory hepatic proteins
associated with the progression of disease. To achieve this, we compared the
relative protein expression in human hepatocyte and HepaRG-based models for
hepatic steatosis with human liver tissue showing progressive stages of NAFLD.
This comprehensive comparison provides a panel of proteins that may act as
probable biomarkers of disease state prediction.
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2. Material and Methods
2.1 Chemicals and Reagents.
TPCK-treated trypsin, trypsin digested β-galactosidase and mass spectrometer
tuning solution were purchased from SCIEX, Framingham, MA. Acquity UPLC Peptide
BEH C18 analytical column and VanGuard pre-columns were procured from Waters Corp.
(Waltham, MA). IN). Bovine serum albumin, sodium deoxycholate and iodoacetamide
(IAA) were procured from Sigma Aldrich (St. Louis, MO). MS grade acetonitrile and formic
acid were purchased from ThermoFisher, Waltham, MA.
2.2 Cell Culture
The HepaRG and cHH were cultured as per manufacturer’s protocol.
Cryopreserved pooled human hepatocytes (cHH). Pooled donors of cHH, were
obtained from Xenotech, LLC (Kansas City, KS). Demographic information of the 5 pooled
cHH is listed in Table 4.1. cHH were thawed in a 37 °C water bath for ~80 seconds. Vials
were inverted transferred to pre-warmed OptiThaw media (K8000). Upon centrifugation at
100 x g for 5 minutes at room temperature or 2-8°C, cells were washed. After thawing, the
cell pellets were resuspended in OptiPlating media. The cells were diluted to 1 million
cells/mL and seeded onto the collagen coated 6-well plate. Following this, the cells were
allowed to attach for 4 h and the media was changed to OptiIncubate Hepatocyte Media
(K8400) and allowed to incubate for 24 h. Upon 24 h, media containing 0.5 mM of fatty
acids (oleate and palmitate 1:2) conjugated to BSA were added to treatment group in
comparison to control. After 72 h of treatment, the cells were washed and scraped
(CELLTREAT Scientific Products, Catalog No. #229310, Pepperell, MA) in ice-cold DPBS
(ThermoFisher Scientific, Catalog No. #14040117, Waltham, MA) and 5-6 million cells
from each replicate was pooled for further analysis.
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HepaRG cells. Frozen undifferentiated HepaRG cells were purchased from Biopredic
International (Rennes, France). The cells were grown for 2 weeks in William’s E media
(ThermoFisher Scientific, Catalog No. #12551032, Waltham, MA), containing 1%
glutamine (ThermoFisher Scientific, Catalog No. # A1286001, Waltham, MA), 1%
penicillin/streptomycin and 10% HepaRG growth supplement (Lonza Inc., Catalog No.
#ADD711C, Walkersville, MD) in 6-well plate. Following growth phase, cells were
differentiated in-house for 2 weeks in William’s E media, 1% glutamine, 1%
penicillin/streptomycin and 10% HepaRG differentiation supplement (Lonza Inc., Catalog
No. #ADD721C, Walkersville, MD) and maintained at 37°C with 21% O2 and 5% CO2
throughout the culture with media changed every 3 days. Upon differentiation, HepaRG
cells were cultured in basal media containing William’s E media, 100 U/mL penicillin, 100
µg/mL streptomycin, 2 mM glutamine, 5 µg/mL insulin (Sigma-Aldrich, Catalog No. #I-034,
St. Louis, MO) and 50 µM hydrocortisone hemisuccinate (Sigma-Aldrich, Catalog No.
#H2270, St. Louis, MO). Upon differentiation, the cells were treated with fatty acid media
as described above. Approximately 8-10 million cells were harvested by cell scraping for
proteomic analysis.

2.3 Oil Red O Staining
Pooled cHH treated with 0.5 mM FA or control for 72h was analyzed for neutral lipid
accumulation. Cells were washed twice with 1X PBS and fixed with 4% paraformaldehyde
(Sigma-Aldrich, Catalog# 100496, Saint Louis, MO) for 30 min in room temperature (RT).
Following this, 500 µl of working Oil Red O (ORO) solution (3 parts of stock ORO and 2
parts of dH2O) (Sigma-Aldrich, Catalog# O0625, Saint Louis, MO) was added and
incubated at RT for 20 min. The cells were washed 3X with distilled water (dH2O), and
500 µL of hematoxylin (Sigma-Aldrich, Catalog# H3136, Saint Louis, MO) was added for
1 min to stain the nuclei and their image was obtained using EVOS cells imaging systems
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(Life Technologies, Model# M7000, Foster City, CA).

The extent of neutral lipid

accumulation was quantified after extraction in 100% isopropanol, and the absorbance
was measured at 492 nm using a SpectraMax plate reader (Molecular Devices, Model#
M2, Sunnyvale, CA).
2.4 Proteomics sample preparation
Cell pellets were homogenized in 500 µl of homogenization buffer (8 M urea, 50
mM Triethylammonium bicarbonate, 10 mM DTT v/v) using a bead homogenizer (Omni
Bead Ruptor, Kennesaw GA). 50 mg of human liver tissue (HLT) (n=116) was
homogenized in 1000 µl of homogenization buffer, in similar fashion. Samples were then
spun at 1,000 g for 5 min and the supernatant was collected. The total protein
concentration was determined using Pierce BCA protein assay (ThermoFisher Scientific,
Catalog No. #23227, Waltham, MA).

2.5 In-solution trypsin digestion
Protein digestion was conducted as previously described with few adaptations.
Samples (250 µg protein) were spiked with 2 µg of BSA and denatured with 25 µL of DTT
(100 mM) at 35°C for 30 min in a shaking water bath (100 rpm) (Precision Scientific,
Catalog No. #66800, Chicago, IL). After denaturation, samples were alkylated in the dark
with 25 µL of IAA (200 mM) for 30 min at room temperature. Samples were then
concentrated using the cold water, methanol and chloroform (1:2:1) precipitation method
(centrifugation at 10000 rpm, 5 min at 10°C) (Eppendorf, Catalog No. #5810 R, Hamburg,
Germany). The protein pellet was washed with ice-cold methanol and suspended in 100
µL of 50 mM ammonium bicarbonate (pH ~8) containing 3% w/v sodium deoxycholate
(DOC). Further, TPCK-treated trypsin (10 µg) was added to samples at a ratio of 1:25
(trypsin: protein) and samples were transferred into digestion tubes (PCT MicroTubes,
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Pressure Biosciences Inc., Easton, MA). The barocycler was run at 35°C, for 75 cycles
with 60-sec pressure-cycle (50-sec high pressure, 10-sec ambient pressure, 25 kpsi).
Subsequently, 10 µg trypsin was added again for futher digestion as mentioned above.
Furthermore, to 110 µL of digested peptides sample, 10 µL of acetonitrile (1:1, v/v
containing 5% formic acid) was added to precipitate DOC. Samples were spun (10,000
rpm for 5 min at 10°C) to remove the precipitate and 100 µL supernatant was collected.
Subsequently, 25 µL of the digested peptide sample was injected on the analytical column
and were analyzed using LC-MS/MS method described below.

2.6 LC-MS/MS method and SWATH-MS data analysis
The LC-MS/MS method was used as previously developed without modifications.
Homogenate samples were analyzed using SWATH-MS based spectra which were
acquired for mass range m/z 400−1100 Da within SWATH window width of 10 m/z
resulting in 70 overlapping mass windows per cycle, as described in the previous
literature21. The DIA data was searched against Swiss-Prot identifiers (October 2016)
and analyzed using Spectronaut™ Pulsar software (version 11.0, Biognosys AG,
Schlieren, Switzerland) was used to obtain MS2 signal intensities of fragment ions from
DIA data using default settings. Raw data files and search results are available at Japan
Proteome

Standard

Repository

(jPOSTrepo

JPST000373,

ProteomeXchange

PXD008594). The SWATH-MS DIA data was matched with the reference spectral library
generated from the DDA of pooled human liver samples using Protein Pilot. The DIA data
was then normalized and analyzed using “Total protein approach” (TPA), as shown below

… (1)
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The absolute protein abundance of each group was represented as pmol/mg of protein.
2.7 Statistical and bioinformatic analysis
Missing data with proteins more than 50% among the samples were omitted from analysis.
For cell analysis, the proteins present in all replicates were only considered for analysis.
Student's t-test with p value < 0.05 and log2FC cutoff of +/- 0.58 was used to identify
differentially expressed proteins in pooled human hepatocytes, and the HepaRG cell lines.
The data obtained from the cells were represented as means from quadruples. Proteins
from human livers were analyzed using SPSS software v24.0. Protein data from human
samples were ln (natural-log) transformed and analyzed using one-way ANOVA and posthoc analysis for multiple group comparison was conducted using Bonferroni test. In
addition, the specificity and selectivity of proteins were analyzed using ROC cures on
SPSS. P< 0.05 was considered significant. Prism 8 (GraphPad Inc., La Jolla, CA) was
used and SPSS 24.0 (IBM Corp., Armonk, NY) were used for graphing and statistical
testing, respectively.
3. Results
3.1 Overall workflow in the identification for dysregulated protein in disease state.
The workflow followed in this manuscript is as illustrated in Fig. 4. 1. The samples obtained
from cell model for hepatic steatosis was analyzed along with human liver tissue with
progressive forms of NAFLD such as: normal (n=42) and NAFL (n=34) based on Kleiner
scoring 5. The data obtained from spectronaut was filtered for missing data and low
abundance proteins which showed highly variable expression pattern. For the cell data,
the proteins selected for analysis were present in all replicates (n=4). Similarly, for human
tissue (n =116) the set criteria were missing data > 50% among all groupings and CV% <
100% owing to the considerable difference caused by the variables considered. In this
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way 2781, 2653, 2580 unique proteins were identified in HLT, cHH and HepaRG cell lines,
respectively (Fig. 4. 1). Among the 2653 protein 40 proteins were dysregulated in hepatic
steatosis. This was compared with HepaRG steatosis model that showed a similar pattern
for 7 proteins as described in Fig. 4. 4. All of these 40 proteins were matched with human
liver tissue and using ANOVA and post hoc analysis for multiple comparison Bonferroni
test (p <0.05), 6 proteins that showed significant difference were identified (Table 4. 3).
3.2.

Effect of fatty acid loading to human hepatocytes.

Upon treatment, the pooled human hepatocytes showed increase in neutral lipid
accumulation visualized at 72h utilizing ORO stain (Fig 4.2A and 4.2B). In addition, we
noticed a 6-fold increase in absorbance (492 nm) when treated with fatty acids in
comparison to the control (p < 0.01) (Fig. 4. 2C).

3.3

SWATH-MS based evaluation of proteins in human hepatocytes, HepaRG and
human liver tissue.

Upon filtering with set criteria, 2781, 2653, 2580 unique proteins were identified in HLT,
cHH and HepaRG cell lines, respectively (Fig. 4.1). Among the groupings, 1967 proteins
were common among the three groups (Fig. 4.2D). However, 130 proteins were present
in HepaRG and HLT independently showing the abundance of biliary-epithelial-like cells
in HepaRG other than the hepatocyte-like cells. In addition, 128 proteins in HLT was not
shared in any other groupings due to the presence of cell types than hepatocytes alone.
3.4

Dysregulated protein expression in hepatic steatosis as seen in human hepatocytes.

In this model for hepatic steatosis, 41 proteins were dysregulated using the cutoff for
log2FC +/- 0.58 and p-value < 0.05 (Fig.4.3C). Among the 40 proteins, 14 were
downregulated (Fig. 4.3A) and 26 were upregulated (Fig.4.3B). Within the 14
downregulated proteins, 5 (PPP1R7, SH3BGRL3, SNX6, NSUN2, PRKACB, RBM4) were
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localized in the nucleus and 3 (EIF5B, NT5C, SLC35A3) in the cytoplasm. Secretory
proteins, PIGR (-0.66), KRT10 (-0.61) and APOE (-0.61) as well as cytoskeleton proteins
CALD1 (-0.95) and PALLD (-0.99) were identified to be significantly downregulated in
steatosis. Moreover, among the 26 dysregulated proteins, 6 secretory proteins HMGB1
(0.62), PDCD5 (0.63), APOA4 (0.78), TSTA3 (1.06), ANAX1 (1.31), LTF (2.33). Other
proteins involved in lipid storage PLIN2 (2.45) as well as those involved in xenobiotic
metabolism GSTA4 (1.13), cytoskeleton remodeling DBNL (0.62) were also upregulated.
3.5

Dysregulated protein expression in hepatic steatosis as seen in combined model of
HepaRG and human hepatocytes.

Among the 40 proteins that were dysregulated in human hepatocytes, 7 proteins showed
a common signature in HepaRG steatosis model as well. KRT10 and APOE were
significantly downregulated. On contrast, TSN, ANXA1, PTMS and PLIN2 showed
upregulation to the extent that is similar between hepatocyte and HepaRG model.
3.6

Dysregulated proteins as possible markers of hepatic steatosis.

The 40 proteins that were dysregulated in pooled human hepatocytes were used as a
starting point to screen for the protein expression in liver tissue showing differential
expression in NAFLD. Among the 40 proteins, 6 showed significant change in expression
in disease state (Table 4.3). It was to be noted that, majority of the protein ANXA1,
GCHFR, H2AFY2, PLIN2, SNX1 and APOE showed a significant change (p < 0.05) in the
earlier stages of the disease with steatosis, hepatocellular ballooning with minimal/no
lobular inflammation (Fig. 4.5). Moreover, PLIN2 showed an increase with progression of
disease from NAFL to NASH (data not shown). Within this pool of 6 proteins, ANAX1 and
APOE were secretory proteins and PLIN2 is associated with lipid droplets present in tissue
as well as plasma.
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The specificity and selectivity of the markers were analyzed using ROC analysis.
All 6 markers showed significance, however, PLIN2, H2AFY2 and ANAX1 showed
ROAUC of ≥ 0.7 showing the potential to be good markers of disease state (Table 4.4).
4

Discussion
Non-alcoholic fatty liver disease (NAFLD) is the estimated, within next 20 years,

the major cause of liver related morbidity and mortality 3. Liver biopsy is the only
confirmatory test for the onset of the disease 1. Due to the invasiveness, substantial cost
as well as variability associated in this testing method, novel non-invasive techniques for
the diagnosis of NAFLD have been extensively studied for development, in the recent
times. The absence of biomarkers at early stages of disease is responsible for late
diagnosis, leading to undiagnosed NAFLD in general population. Therefore, identifying
novel biomarkers to detect the onset of the disease as well as disease progression is the
need of the hour.
Proteomics is emerging as an efficient tool for its application in exploratory
biomarker studies12. DIA based SWATH-MS approach is sensitive and highly reproducible
method to measure low abundant proteins in complex biological matrices

10, 11, 15

. Hence,

SWATH-MS approach was used to screen our samples as illustrated in Fig. 1. The global
proteome expression, in the invitro HepaRG and hepatocyte model for steatosis was
compared with human liver tissue with varying degrees of NAFLD. In addition, the whole
cell and tissue homogenate without fractionation was analyzed as it most closely
resembled the physiological state.
Upon analyzing the samples, the dysregulated proteins in human hepatocytes
model for hepatic steatosis was performed using log2FC and pvalue < 0.05 (Figures 3A–
C). A few of the dysregulated proteins observed in human hepatocytes (PIGR, APOE,
ANXA, KRT10) are identified in exosomes released from the mouse model of NAFLD,
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which validates the prominence of these markers in disease state

16

. Furthermore, our

analysis from liver samples from different stages of NAFLD demonstrate that PLIN2,
ANXA1, GCHFR, SNX1, H2AFY2 and APOE were significantly altered in NAFLD in
comparison to control groups. Moreover, PLIN2 and H2AFY2 showed log fold change
(logFC) greater than 0.58 showing more pronounced deregulation. In addition, ROC
analysis highlights the selectivity and sensitivity of the markers individually on the disease
state prediction (Table 4). It shows that PLIN2, ANXA1 and H2AFY2 are good markers of
disease state with ROAUC ≥ 0.7.
It is important to note that most of the markers showed an altered expression
pattern in the earlier stages of the disease (NAFL) rather than those observed in NASH
(data not shown). This pattern could be because of the bias associated with the
comparison of dysregulated proteins from the hepatocyte-steatosis model. Furthermore,
the sample size is not large enough to conclude the markers definitively to predict NAFL.
Hence, studies with larger sample sizes need to conducted to make more conclusive
remarks.
PLIN2 is an abundant hepatic protein associated with lipid droplets. Reports show
staining pattern of perilipin to distinguish steatosis and non-alcoholic steatohepatitis in
adults and pediatric population

17

. In addition, PLIN2 is concentrated and detected in

human urine and is used to differentiate renal carcinomas 18. However, it is a ubiquitous
protein associated with adipocytes differentiation, protumorigenesis and steatosis in
cardiomyocytes. Hence, its selectivity for a disease state prediction may lead to low
confidence. Therefore, PLIN2 along with other markers needs to be assessed together for
understanding NAFLD. ANXA1 is an anti-inflammatory protein secreted by the
hepatocytes. Plasma levels of ANXA1 are shown to correlate with fatty liver index in type
2 diabetes patients

19

. Additionally, its role is speculated to attenuate insulin resistance
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and hepatosteatosis. The evidences in literature alongside our observation in disease
state suggest the probable role AnnexinA1 as a biomarker for NAFL. Nuclear protein
H2AFY2, a variant of histone protein H2A is a repressor of gene expression and APOE is
a lipoprotein secreted by the hepatocyte that is required for VLDL clearance from the
blood. The role of GCHFR and SNX1 is yet to be explored in NAFLD.
Many previous studies have explored the potential of multiple plasma proteins as
biomarkers of NAFLD 9, 20. Most studies, focus on the hallmarks of the disease progression
that is inflammation and fibrosis. Thereby, we notice the promising biomarkers in plasma
known thus far, such as: adiponectin, CRP, resistin, leptin, RBP-4, IL-6 and TNFα in
inflammation and fibrosis; CK-18 fragments in apoptosis; MCP-1 in hepatocellular
ballooning; ALT levels in hepatocellular injury; as well as ferritin in fibrosis. However, there
is not much know about the early stage predictors of the disease. Hence our work is novel
in presenting the dysregulated proteins in earlier stages of NAFLD prior to the onset of
NASH.
In summary, a DIA based proteomics using SWATH-MS was implemented to
understand the relevant proteins in NAFLD progression. Furthermore, by utilizing in-vitro
model for steatosis we were able to delineate the proteins associated particular to the
changes in fatty-acid overload. With this approach we streamlined 6 proteins including 2
secretory proteins (ANAX1 and APOE) along with PLIN2 that is all localized ubiquitously
with lipid droplets. Our work adds valuable information for future investigations and clinical
biomarker research.
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5

Figure and Tables
Human hepatocyte
model for
hepatic steatosis
(n = 4 of 5 pooled
donors)

HepaRG model for
hepatic steatosis
(n = 4 of passage
17 - 20)

Number of proteins
(identified in all replicates &
CV% < 40%)
2653

Number of proteins
(proteins identified in all
replicates; CV% < 40%)
2580

SWATH-MS

Human liver tissue
with normal (n=42)
and NAFLD (n=34)

Number of proteins
(50% missing data; CV% <
100%)
2781

Filtered based on:
log2FC > 0.58 (or)
log2FC< -0.58;
p-value < 0.05

Number of proteins
40
Combined model
Number of proteins
7

Filtered based on: oneway ANOVA and
Bonferroni test for
multiple comparison
P<0.05

Probable markers
of disease state
6

Figure 4.1: Overview of the workflow followed in the biomarker identification.
The HepaRG and pooled human hepatocytes model for hepatic steatosis were collected and
analyzed using SWATH-MS. Simultaneously human liver tissue (n=116) homogenates were
screened using SWATH-MS and the data was analyzed using spectronaut. Using set criteria, the
number of proteins identified in the groups were 2580, 2653 and 2781 in HepaRG, human
hepatocytes and human liver tissue, respectively. Finally, the dysregulated from human
hepatocytes was matched with human liver tissue to identify 6 markers of disease state.

151

Figure 4.2: Hepatic steatosis in human hepatocytes.
Accumulation of neutral lipids upon the addition of fatty acid mixture to the pooled human
hepatocytes is shown in the panel A and B. (C) Shows the 6-fold increase in the
absorbance of neutral lipids in the treatment when compared to the control. The results
are represented as mean of quadruple with p < 0.01. (D) Shows the Venn diagram of the
number of identified proteins in human liver tissue, hepatocytes and HepaRG, with 1967
proteins were common among all groups.
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Figure 4.3: Dysregulated protein expression in FA treatment and control in human
hepatocytes.
(A) Heat map of downregulated proteins in human hepatocytes (B) Heat map of upregulated
proteins in human hepatocytes (C) The volcano plot shows green spots that indicate the
upregulated proteins in human hepatocytes (log2FC>0.58 and Pvalue<0.05). The red spots
indicate the downregulated proteins in human hepatocytes (log2FC<0.58 and Pvalue<0.05).
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Figure 4.4: Comparison of protein changes in FA treatment and control in HepaRG
model and human hepatocytes.
Figure shows proteins that were regulated with p-value <0.05.
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Figure 4.5: Hepatic protein expression shows differential expression in human liver
tissue grouped based on control and NAFL.
The differential expression in control (n=42) and NAFL (n=34) in human liver tissue. * denotes P
value < 0.05 and ** denotes P-value < 0.01 using Bonferroni multiple comparison on lntransformation.
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Table 4.1 Demographic information of human liver samples
N
Age (y)
Female
Male
Caucasian
Afro-American
Hispanic
Body weight (kg)
BMI (kg/m2)

Control
42
46.5 (41.9 - 51.6)
16
26
33
8
1
83.5 (76.2 - 91.5)
29.3 (26.5 - 32.3)

NAFL
34
52.8 (49.5 - 56.4)
19
15
20
1
3
89.8 (80.6 - 100.1)
31.2 (28 - 34.8)
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Table 4.2: Demographic information of pooled human hepatocytes.

N
Age (y)
Female
Male
Caucasian
Afro-American
Asian
Cause of death
Antibody to
cytomegalovirus
(CMV)

Pooled human
hepatocyte
5
24 - 57 years
2
3
3
1
1
Head trauma (1);
Cerebrovascular
accident (3)
Positive (4); Negative
(1)
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Table 4.3: Data summary of the significantly altered proteins in NAFLD
Normal
Mean
N
PLIN2
ANXA1
H2AFY2
SNX1
GCHFR
APOE

0.61
2.80
0.24
0.51
24.02
2.48

42
42
42
42
42
42

95% CI
lower
upper
bound
bound
0.48
0.79
2.49
3.15
0.20
0.27
0.48
0.54
22.10
26.11
2.21
2.78

NAFLD
Mean
N
1.51**
3.81**
0.41**
0.58*
19.48*
3.07*

35
35
35
35
35
35

95% CI
lower
upper
bound
bound
1.08
2.11
3.26
4.44
0.34
0.48
0.54
0.63
17.50
21.69
2.74
3.43

log2FC

1.29
0.44
0.79
0.20
-0.30
0.31
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ABBREVIATION: CI - Confidence Interval; FC - Fold Change; N = no. of subjects; PLIN2 - Perilipin 2; ANXA1 - Annexin A1; H2AFY2 - Core
Histone; SNX1 - Sorting protein 1; GCHFR - GTP Cyclohydrolase I Feedback Regulator; APOE - Apolipoprotein E. The differential
expression in human liver tissue. * denotes P value < 0.05 and ** denotes P-value < 0.01 using Bonferroni multiple comparison on one-way
ANOVA

Table 4.4: Receiver Operative Curve (ROC) Analysis for the markers of disease
state.
Area
Std.
Under
Errora
Curve
(ROAUC)
PLIN2
ANXA1
H2AFY2
SNX1
GCHFR
APOE

0.770
0.700
0.798
0.669
0.688
0.688

0.056
0.061
0.055
0.063
0.061
0.061

Asymptotic
Sig.b

0.000
0.003
0.001
0.011
0.005
0.005

ABBREVIATION: ROAUC - Reciever operative Area Under the Curve; PLIN2 - Perilipin 2;
ANXA1 - Annexin A1; H2AFY2 - Core Histone; SNX1 - Sorting protein 1; GCHFR - GTP
Cyclohydrolase I Feedback Regulator; APOE - Apolipoprotein E. The differential
expression in human liver tissue. * denotes P value < 0.05 and ** denotes P-value < 0.01 using
Bonferroni multiple comparison on one-way ANOVA.
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Table 4.5: Dysregulated proteins in hepatic steatosis using a human hepatocyte model.
Protein Symbol

Protein Name

Molecular process

Log2(FC)

Secretory protein

ANXA1

Annexin A1

Immune response

1.31*

APOA4

Apolipoprotein A-IV

0.78

APOE

Apolipoprotein E

Cholestrol efflux, lipid homoestatis
and lipid transport
APOE vital lipoprotein metabolism

0.62*

HMGB1

High mobility group protein B1

Promotes inflamatory response

0.62

KRT10

Keratin, type I cytoskeletal 10

KT10 dysregulation leads to
impaired NF-kB activity via
inhibition of Akt

-0.59

LTF

Lactotransferrin

2.33

PDCD5

Programmed cell death protein
5

Negative regulator of
lipopolysccaride mediated
signalling pathway
Apoptosis

PIGR

Polymeric immunoglobulin
receptor
GDP-L-fucose synthase

Neutophil degranulation

-0.66

T cell mediated cytotoxicity

1.06

Activation of AKT1 pathway in
insulin response
Translation initaition

1.21
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Localization

TSTA3

Nuclear proteins

APPL1
EIF4H

DCC-interacting protein 13alpha
Eukaryotic translation initiation
factor 4H

0.63

0.62

GCHFR

GTP Cyclohydrolase I
Feedback Regulator
RNA cytosine C(5)methyltransferase NSUN2
Protein phosphatase 1
regulatory subunit 7

Phenylalanine metabolism and
nitric oxide production
Cell division

0.65*

Positive regulator of protein
dephosphorylation

-0.63

PRKACB

cAMP-dependent protein
kinase catalytic subunit beta

Cellular response to glycogen
synthesis

-0.82

PTMS

Parathymosin

Immune response

0.76

RBM5

RNA-binding protein 5

Apopotoptic pocess

0.95

RBM4

RNA-binding protein 4

RNA binding protein

-1.31

SH3BGRL3

SH3 domain-binding glutamic
acid-rich-like protein 3

Cell redox homeostatis

-0.65

SNX1

Sorting nexin-1

Intracellular protein transport

0.64*

SNX6

Sorting nexin-1

Intracellular protein transport

-0.71

TSN

Tanslin

1.02

H2AFY2

Core histone macro-H2A.2

Stimulates RNAi production for
silencing the transcript from protein
expression
Keratinocyte differentiation;
regulation of gene expression

GSTA4

Glutathione S-transferase A4

NSUN2
PPP1R7

161
Cytoplasmic
protein

Xenobiotic metabolism

0.81

0.92*

1.13

GMPPA

Mannose-1-phosphate
guanyltransferase alpha

Formation of glycolipids

0.82

NBPF7

Putative neuroblastoma
breakpoint family member 7

unknown

1.01

EIF5B

Eukaryotic translation initiation
factor 5B
5'(3')-deoxyribonucleotidase,
cytosolic type

Translational initiation

0.62

Purine catabolism

-0.77

CALD1

Caldesmon

-0.95

PALLD

Palladin

DBNL

Drebrin-like protein

Increase the stiffness of actin
filament and promote cellular
contraction
Increase the stiffness of actin
filament and promote cellular
contraction
Reorganization of actin
cytoskeleton

ATP1A2

Sodium/potassium-transporting
ATPase subunit alpha-2

Sodium potasium transporter
involved in wide range of
processes

0.92

CLTB

Clathrin light chain B

Translational initiation

0.65

NT5C

162
Cytoskeletal
proteins

Membrane protein

-0.99
0.62

Other
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RAB23

Ras-related protein Rab-23

Intracellular protein transport

0.86

SLC26A2

Sulfate transporter

Sulfate transporters involved in
bone formation

0.95

PLIN2

Perilipin-2

Lipid storage

2.45*

G6PC

Glucose-6-phosphatase

Converts glucose 6 phosphate to
glucose

0.58

BCAT2

Branched-chain-amino-acid
aminotransferase

0.58

SLC35A3

UDP-N-acetylglucosamine
transporter

Induce heterogenecity in LD in
hepatocytes; BCAA are indicative
hepatic stress
Carbohydrate transport

Footnote - *indicate proteins that showed a significant change in expression in human liver tissue

-0.98
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CONCLUSIONARY REMARKS
This work demonstrates the utility of in vitro models of hepatocytes to aid in the
identification of novel biomarkers in hepatic steatosis. In the first part of this work
(Manuscripts II), we characterized different cell lines to choose the appropriate human
carcinoma cell line for model development in NAFLD. Using this initial assessment,
HepaRG cell line was chosen for model development with lipid loading using oleate and
palmitate (1:2) at 0.5 mM for 72 h (Manuscript III). With transcriptomics and proteomics
technologies we noticed differential expression of numerous transcripts and proteins
involved in lipogenesis, lipid transport and hepatocellular injury. In the transcript levels, we
identified significant down-regulation of PXR, CAR and HNF4α as well as its target drug
metabolizing enzymes CYP1A2, 2B6, 2C8, 2C9,2C19 and 3A4, phase 2 DMEs including
UGT1A6 and 2B7, SULT2A1 and 1E1. In the protein level, lower trends of cytochrome
P450 were observed, however the difference was not statistically significant. The
variability associated with the increasing passage number in HepaRG cell line as well as
the changes involved in the biological processes such protein stabilization, or the relative
half-life of mRNA in comparison to proteins may have contributed to this variability
observed.
In the final part of the dissertation, we adapted the model, developed in HepaRG to
human hepatocytes where the fat over-load led to 6-fold increase in neutral lipid
accumulation in hepatocytes showing the characteristics of hepatic steatosis model
(Manuscript IV). In addition, 40 proteins showed a significant change in human
hepatocyte model for steatosis assessed using SWATH-MS. When these proteins were
screened in human liver tissue with progressive stages of NAFLD we noticed 6 proteins
including 2 secretory protein that have the potency to predict the early stages of disease
state.
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We believe this work that is a conjunction of in vitro model NAFLD along with the
SWATH-MS, DIA based proteomics approach provides vital information for the
identification of novel biomarkers to predict the early stages of the disease. We believe
this will help in diagnosis of NAFLD in stages prior to NASH that may aid in more effective
treatment before the disease had developed to more progressive stages. In addition, we
believe these proteins may also have the potential as predictive biomarkers in treatment
and therapy.
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